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Background: For patients referred to hospital with suspected colorectal cancer (CRC), it is current
standard clinical practice to conduct an examination of the whole colon and rectum. However, studies
have shown that an examination of the distal colorectum using flexible sigmoidoscopy (FS) can be a
safe and clinically effective investigation for some patients. These findings require validation in a
multicentre study.
Objectives: To investigate the links between patient symptoms at presentation and CRC risk by subsite,
and to provide evidence of whether or not FS is an effective alternative to whole-colon investigation (WCI)
in patients whose symptoms do not suggest proximal or obstructive disease.
Design: A multicentre retrospective study using data collected prospectively from two randomised
controlled trials. Additional data were collected from trial diagnostic procedure reports and hospital
records. CRC diagnoses within 3 years of referral were sourced from hospital records and national cancer
registries via the Health and Social Care Information Centre.
Setting: Participants were recruited to the two randomised controlled trials from 21 NHS hospitals in
England between 2004 and 2007.
Participants: Men and women aged ≥ 55 years referred to secondary care for the investigation of
symptoms suggestive of CRC.
Main outcome measure: Diagnostic yield of CRC at distal (to the splenic flexure) and proximal subsites
by symptoms/clinical signs at presentation.
DOI: 10.3310/hta21660 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 66
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Atkin et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
vii
Results: The data set for analysis comprised 7380 patients, of whom 59% were women (median age
69 years, interquartile range 62–76 years). Change in bowel habit (CIBH) was the most frequently presenting
symptom (73%), followed by rectal bleeding (38%) and abdominal pain (29%); 26% of patients had
anaemia. CRC was diagnosed in 551 patients (7.5%): 424 (77%) patients with distal CRC, 122 (22%)
patients with cancer proximal to the descending colon and five patients with both proximal and distal CRC.
Proximal cancer was diagnosed in 96 out of 2021 (4.8%) patients with anaemia and/or an abdominal mass.
The yield of proximal cancer in patients without anaemia or an abdominal mass who presented with rectal
bleeding with or without a CIBH or with a CIBH to looser and/or more frequent stools as a single symptom
was low (0.5%). These low-risk groups for proximal cancer accounted for 41% (3032/7380) of the cohort;
only three proximal cancers were diagnosed in 814 low-risk patients examined by FS (diagnostic yield 0.4%).
Limitations: A limitation to this study is that changes to practice since the trial ended, such as new
referral guidelines and improvements in endoscopy quality, potentially weaken the generalisability of
our findings.
Conclusions: Symptom profiles can be used to determine whether or not WCI is necessary. Most proximal
cancers were diagnosed in patients who presented with anaemia and/or an abdominal mass. In patients
without anaemia or an abdominal mass, proximal cancer diagnoses were rare in those with rectal bleeding
with or without a CIBH or with a CIBH to looser and/or more frequent stools as a single symptom. FS
alone should be a safe and clinically effective investigation in these patients. A cost-effectiveness analysis
of symptom-based tailoring of diagnostic investigations for CRC is recommended.
Trial registration: Current Controlled Trials ISRCTN95152621.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 21, No. 66.
See the NIHR Journals Library website for further project information.
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FIGURE 1 The SOCCER study profile 15
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ACPGBI Association of Coloproctology of
Great Britain and Ireland
CI confidence interval
CIBH change in bowel habit
CRC colorectal cancer
CT computerised tomography





HSCIC Health and Social Care Information
Centre
IDA iron deficiency anaemia
MCV mean corpuscular volume
NICE National Institute for Health and
Care Excellence
SIGGAR Special Interest Group in
Gastrointestinal and Abdominal
Radiology
SOCCER Symptoms of Colorectal Cancer
Evaluation Research
WCI whole-colon investigation
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What was the problem?
Diagnosing bowel cancer involves the examination of the whole large bowel. This can be unpleasant,
carries risks, including the potential for damage to the bowel, and is costly. Evidence suggests that some
patients could be investigated effectively by flexible sigmoidoscopy (FS), which examines the lower large
bowel only. The benefits of FS are that it is safer and quicker than whole-bowel examination. A downside
is that cancers in the upper large bowel could be missed, and this risk needs to be investigated.
What did we do?
We analysed whether or not symptoms could predict the location of bowel cancer in 7380 patients
referred to 21 hospitals across England. We also determined how many cancers would have been missed
if FS had been performed instead of whole-bowel examination.
What did we find?
Anaemia is common in patients with bowel cancer. Patients with anaemia or an abdominal mass were
most likely to be diagnosed with cancer in the upper large bowel. In patients without anaemia or an
abdominal mass, only 6 per 1000 with rectal bleeding and none with a change in bowel habit to looser
and/or more frequent stools had cancer in the upper large bowel.
What does this mean?
For patients with certain symptoms, FS can be a clinically effective investigation and it is likely that very
few upper large bowel cancers would be missed. The potential cost savings for the NHS require
further analysis.
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With > 40,000 new diagnoses in the UK each year and an annual NHS expenditure of > £1B, to which
diagnostic investigations are the single largest contributor, colorectal cancer (CRC) is a health priority area.
The presenting features known to be associated with CRC are typically vague, and diagnostic yields for
investigations are often low. It is current clinical practice to examine the whole large bowel when CRC is
suspected in symptomatic patients because of the perceived risk of missing a cancer in the proximal colon
when only the distal colorectum is examined by flexible sigmoidoscopy (FS). This is despite evidence of low
predictive values of certain CRC symptoms for proximal cancer and the risks/disadvantages of whole-colon
investigations (WCIs). In a single-centre study in Portsmouth, England, of 16,433 patients with suspected
CRC, > 95% of cancers were detected by FS in patients found not to have iron deficiency anaemia (IDA)
or an abdominal mass. This study, and others, suggested that an examination of the distal colorectum
by FS is adequate for the majority of patients with distal features of this disease. Further assessment is
required of CRC diagnostic yields in the proximal and distal colorectum by presenting features in the wider
secondary care population, along with assessment of the diagnostic accuracy of FS for CRC in patients
presenting with distal features. This information could be used to inform national guidelines and clinical
practice to optimise diagnostic investigations for suspected CRC.
Objectives
The primary research objective is to:
l investigate the link between symptoms at presentation and proximal colon cancer risk, and provide
evidence of whether or not FS is a clinically effective alternative to WCI in patients whose symptoms do
not suggest proximal disease.
The secondary research objectives are to:
l determine the diagnostic miss rate of FS for cancers in the colon and rectum
l determine the prevalence of proximal and distal CRC in patients referred to hospital with symptoms
suggestive of CRC.
Methods
The Symptoms of Colorectal Cancer Evaluation Research (SOCCER) study was proposed as an additional
analysis of data collected for the Special Interest Group in Gastrointestinal and Abdominal Radiology
(SIGGAR) randomised controlled trials [Halligan S, Dadswell E, Wooldrage K, Wardle J, von Wagner C,
Lilford R, et al. Computed tomographic colonography compared with colonoscopy or barium enema for
diagnosis of colorectal cancer in older symptomatic patients: two multicentre randomised trials with
economic evaluation (the SIGGAR trials). Health Technol Assess 2015;19(54)]. These trials investigated the
clinical effectiveness and cost-effectiveness of computerised tomography colonography compared with
colonoscopy or barium enema in the diagnosis of CRC and significant polyps (≥ 10 mm). During the
SIGGAR trials, all symptoms/clinical signs at referral were recorded at eligibility assessment. Potentially
eligible patients were those experiencing symptoms suggestive of CRC, aged ≥ 55 years, clinically judged
to need a WCI, judged as fit to undergo full bowel preparation and able to give informed consent. Patients
were identified from outpatient clinics and endoscopy and radiology procedural lists, and included
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suspected cancer 2-week-wait, urgent and routine referrals. Consenting eligible patients were randomised
during the SIGGAR trials. To enhance the generalisability of the SOCCER study findings to the broader
secondary care population, patients who had been assessed as potentially eligible for SIGGAR were
included in the SOCCER study, whether or not they had been randomised.
Baseline symptoms, referral pathways and planned investigations for all patients were recorded during the
SIGGAR eligibility assessment on bespoke pro formas, and this information was transferred to a SOCCER
study database for analysis. Additional information to supplement that collected at baseline during the
SIGGAR trials that pertained to symptoms and CRC diagnoses was collected from SIGGAR trial reports and
hospital endoscopy, radiology, surgery and pathology records.
For patients for whom blood test data were available, anaemia/IDA was defined as laboratory-confirmed
anaemia/IDA within 6 months before and 3 months after the date of referral. For patients with a diagnosis of
CRC, blood tests dated on or after the date of diagnosis were excluded. Blood test parameters [haemoglobin
(Hb) level (g/dl), mean corpuscular volume (MCV; fl) and serum ferritin (µg/l)] were collected from hospital
haematology databases. When multiple results were available for a patient, the lowest recorded values were
selected. We considered four different definitions of anaemia: broad anaemia, strict anaemia, broad IDA and
strict IDA. Broad anaemia was defined solely by Hb level: < 13 g/dl in males and < 12 g/dl in females. Strict
anaemia was defined as a Hb level of < 11 g/dl in males and < 10 g/dl in females, or as a Hb level of ≥ 11 g/dl
but < 13 g/dl in males or ≥ 10 g/dl but < 12 g/dl in females accompanied by microcytosis (MCV < 80 fl) or
low ferritin (< 20 µg/l). Broad IDA was defined as a Hb level of < 13 g/dl in males and < 12 g/dl in females
accompanied by microcytosis (MCV < 80 fl) or low ferritin (< 20 µg/l). Strict IDA was defined as a Hb level of
< 13 g/dl in males and < 12 g/dl in females accompanied by low ferritin (< 20 µg/l). For patients without
blood test data, anaemia was defined by its inclusion on the SIGGAR trial pro forma.
The diagnostic accuracy of symptoms/clinical signs at presentation for site of cancer (proximal vs. distal)
was estimated from CRC diagnoses up to 3 years post referral. Cancer diagnoses were obtained from
registries via the Health and Social Care Information Centre (HSCIC) and hospital records. Cancers were
classified as ‘distal’ if they were located in the anus, rectum, sigmoid colon or descending colon. Cancers
located at colonic sites proximal to the descending colon were classed as ‘proximal’. The sensitivities,
diagnostic yields and numbers that needed to be examined to diagnose one cancer by presenting features
were calculated for proximal and distal cancers. FS miss rates by clinical features for CRC were calculated
in patients examined by FS at referral. The results were presented as percentages with 95% binomial exact
confidence intervals.
Results
During the SIGGAR trials, 8484 patients with symptoms suggestive of CRC were registered as potentially
eligible. For the purposes of the SOCCER study, 1104 patients were excluded prior to analysis: 936 who
dissented to the use of their data in future research, 75 who were judged by a clinician as unable to
provide informed consent for the use of their data in future research, 27 for whom no symptoms/clinical
signs were recorded at presentation, 10 who had duplicate study records and 56 patients who could not
be traced through the HSCIC. The final SOCCER cohort analysed comprised 7380 patients (4353 women;
59%). The median age of the cohort was 69 years (interquartile range 62–76 years). The majority of
patients were referred via colorectal surgical outpatient clinics (84.5%) and under the suspected cancer
2-week wait pathway (53.9%). We obtained laboratory-confirmed anaemia status for 4741 (64.2%)
patients. There were some differences between the patient cohorts with and without blood test data.
The patients with blood test data were slightly older (p < 0.001), less likely to be referred via a colorectal
outpatient clinic (p < 0.001) and more likely to be 2-week wait referrals (p < 0.001). Patients with blood
test data were also more likely to present with weight loss (p < 0.001) and less likely to present with rectal
bleeding (p < 0.001). In the cohort overall, 551 patients were diagnosed with CRC. Overall, the majority of
these patients (n = 429, 77.9%) had distal cancer. Distal cancer was less common in the cohort with blood
test data (5.1% vs. 7.2% in the cohort without blood test data; p < 0.001), whereas proximal cancer was
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more common in the cohort with blood test data (2.0% vs. 1.2% in the cohort without blood test
data; p = 0.007).
Clinical features at referral
In the cohort overall (n = 7380), a change in bowel habit (CIBH) and rectal bleeding were the most
frequently presenting symptoms. Over 72% (n = 5382) of patients presented with a symptom profile
including a CIBH and more than one-third of patients (37.6%) presented with rectal bleeding.
Rectal bleeding and rectal mass were more common in patients without blood test data (42.2% and
3.2%, respectively) than in those with blood test data (35.0% and 1.7%, respectively; both p < 0.001).
Among 4741 patients with blood test data, the proportions with laboratory-confirmed anaemia depended
on the definition of anaemia. Using the broadest definition, 35.0% (n = 1659) of patients were anaemic,
whereas 12.0% (n = 567) of patients presented with broad-definition IDA and 6.7% (n = 318) presented
with strict-definition IDA. Some clinical features, such as abdominal pain, abdominal mass and a CIBH
(except to harder stools and/or less frequent defecation), were more common in women (p ≤ 0.03),
whereas more men than women presented with rectal bleeding (p < 0.001) or anaemia (p < 0.001).
The prevalence of rectal bleeding was lower in older than in younger men (27.8% vs. 44.5%) and higher
in men than in women (22.8% vs. 37.8%). By contrast, anaemia was substantially more common in older
than in younger men (73.3% vs. 23.8%) and more common in men than women (57.2% vs. 18.6%) for
the broad definition of anaemia. Similar trends for anaemia by age were observed irrespective of the
anaemia definition.
Sensitivity of clinical features for distal and proximal cancers
The sensitivity of any symptom for distal cancer was highest for a CIBH (72%), either in combination with
other symptoms or as an isolated symptom. A CIBH was more sensitive for distal than for proximal cancer
(71.7% vs. 54.2%; p = 0.002). The sensitivity of rectal bleeding for distal cancer was 64.2%, which was
approximately three times higher than for proximal cancer (20.8%; p < 0.001). Anaemia was the most
sensitive feature for proximal cancer and was more sensitive for proximal than for distal cancer (p < 0.001).
More than 80% of patients with proximal cancer presented with a symptom profile including anaemia
(by the broadest definition).
We examined the most common features (a CIBH, rectal bleeding and anaemia) in further detail in the full
cohort of 7380 patients. Overall, 91% of 321 patients diagnosed with cancer who presented without
anaemia or an abdominal mass had distal cancer. Of the patients without anaemia or an abdominal mass,
94% (221/234) of those diagnosed with cancer who presented with rectal bleeding had distal tumours.
Of patients without anaemia, abdominal mass or rectal bleeding, who presented with a CIBH to looser
and/or more frequent stools and were diagnosed with cancer, 100% (15/15) had distal cancer.
Diagnostic yields of clinical features for distal and proximal cancers
Anaemia and abdominal mass were highly predictive of both proximal and distal cancers. In the full cohort
of 7380 patients, 2021 patients had either anaemia or an abdominal mass. These clinical features resulted
in diagnostic yields of 4.8% for proximal cancer and 6.7% for distal cancer. No other feature exhibited
proximal cancer diagnostic yields of more than approximately 1% and the number of patients that needed
to be examined to diagnose one proximal cancer in patients without anaemia or an abdominal mass
ranged from 75 to 293. Distal cancer diagnostic yields were generally higher than proximal cancer
diagnostic yields, which was reflected in the lower numbers needed to be examined to diagnose one distal
cancer (range 6–121). More than 1 in 14 patients with rectal bleeding alone (yield 7.5%) or rectal bleeding
with a CIBH (yield 11.6%) were diagnosed with distal cancer. The findings were similar in the cohort who
had blood test data available.
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Flexible sigmoidoscopy examinations and cancer miss rates
Out of the 7380 patients, 20% (n = 1483) received a FS examination at referral. Patients examined by FS
were more likely to present with rectal bleeding (41.3% vs. 36.6%; p = 0.001), abdominal pain (32.1% vs.
28.0%; p = 0.002) or rectal mass (3.2% vs. 2.0%; p = 0.007). Anaemia was more likely to be reported in
the cohort without a FS examination (p < 0.001). Proportionately more cancers were diagnosed in patients
examined by FS than in patients not examined by FS (9.6% vs. 6.9%; p < 0.001). Proportionately more
patients examined by FS than not examined by FS were diagnosed with distal cancer (7.6% vs. 5.4%;
p = 0.0014), but the rates of proximal cancer were not significantly different between these subgroups
(p = 0.22). Over 78% (n = 112) of the 142 patients examined by FS and subsequently diagnosed with
cancer had distal tumours; 101 (90.2%) of these patients had cancer identified at FS and only 11 patients
were subsequently diagnosed with distal cancer when cancer had not been identified at FS. Of these
11 patients, only three had ‘complete and normal FS’; the remainder had other findings at FS (n = 2) or
incomplete FS (n = 6). In the FS group, 31 patients were subsequently diagnosed with proximal cancer and,
of these, 22 (71.0%) were patients who had a ‘complete and normal’ FS.
In 493 patients who presented with rectal bleeding without anaemia or an abdominal mass, 94.5%
(n = 69) of the 73 distal cancers were identified at FS. Of the three patients in this subset diagnosed with
proximal cancer, two had findings at FS that might have warranted a WCI (in one patient cancer was
identified at FS and in one patient three or more lesions were detected). A total of 578 patients presented
with a CIBH without anaemia, an abdominal mass or rectal bleeding, 18 of whom were diagnosed with
cancer. Only three patients examined by FS who presented with a CIBH were diagnosed with proximal
cancer, none of whom had a CIBH to looser and/or more frequent stools. In patients presenting with
anaemia or an abdominal mass (n = 359), 78% (n = 18) of distal cancers were identified at FS. Only one
patient was subsequently diagnosed with distal cancer after a ‘complete and normal’ FS. However,
25 (52%) out of 48 patients with cancer in this group had a proximal tumour and 19 (76.0%) of these
patients had a ‘complete and normal’ FS.
Conclusions
The diagnostic yield of proximal colon cancer was highest in patients presenting with anaemia or an
abdominal mass. The rates of distal CRC were also comparatively high in these patients. By contrast, certain
features that were present in a large proportion of patients were associated with relatively low risk of
proximal cancer compared with anaemia/abdominal mass. Proximal cancer diagnoses were rare in patients
presenting with rectal bleeding or a CIBH to looser and/or more frequent stools, a subgroup that constituted
40% of the total cohort. Our findings now add to the body of evidence supporting recommendations,
which have yet to become standard practice, for tailoring diagnostic investigations for suspected CRC based
on presenting features. As diagnostics is the single largest contributor to the £1.1B NHS cost associated with
CRC, a cost-effectiveness analysis of symptom-based tailoring of diagnostic investigations for suspected CRC
is recommended.
Trial registration
This trial is registered as ISRCTN95152621.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Colorectal cancer diagnosis: the health service burden
Colorectal cancer (CRC), also known as bowel cancer, is a UK health priority. Over 40,000 men and
women were newly diagnosed with this disease in the UK in 2012, and > 16,000 people died from it.1
More than £1B in NHS expenditure per year was attributed to CRC management in a 2007 cost-of-illness
evaluation, which included costs for screening and diagnosis through to those for treatment and palliative
care.2 Diagnostic costs were the single largest contributor to CRC NHS expenditure, accounting for
approximately £291M (26%) of the total expenditure.2 The overwhelming majority of CRC diagnostic costs
(£270M; 92.9%) was attributed to investigations in those subsequently not found to have the disease.2
The high costs associated with CRC diagnosis are likely to be a result of the very common nature of bowel
cancer symptoms, as a result of which the majority of patients investigated will not have bowel cancer,
and the high costs of the diagnostic tests used to investigate patients for suspected CRC. This is probably
compounded by the lack of a cheaper, reliable, immediate test to triage patients.
In symptomatic patients, the recommended investigation for suspected CRC is endoscopic evaluation
[by colonoscopy or flexible sigmoidoscopy (FS)], radiological imaging [by computerised tomography (CT)
colonography or barium enema], or a combination of procedures, ‘where the aim is to achieve adequate
visualisation of the entire colon and rectum’.3 The choice of investigation depends on clinician and
patient preference, local expertise and patient age/comorbidities.3 In 2013/14, approximately 530,000
colonoscopies and 300,000 FS were performed in the NHS, compared with 60,000 CT colonography and
2000 barium enema evaluations.4 In the UK, endoscopy services are currently overwhelmed by demand
and under pressure to meet urgent referral targets.4 As an indication of the increasing pressures on
endoscopy services, it has been predicted that by 2020 an additional 750,000 endoscopies will be required
per year to meet demand, which is a 44% increase on 2013/14.4
Endoscopic whole-colon investigation: colonoscopy
In accordance with the National Institute for Health and Care Excellence (NICE) clinical guidelines,
colonoscopy is the reference standard test for establishing a diagnosis of CRC.3 The advantages of this
procedure are that it can visualise the whole colorectum, has high sensitivity for CRC and also permits biopsy
and the removal of lesions.3 Colonoscopy is, however, an invasive procedure that is associated with a small
risk of serious complications, including heavy bleeding (1 in 150), bowel perforation (1 in 1500) and,
although rarely, death (approximately 1 in 10,000).5 Colonoscopy can also be an uncomfortable experience
for some patients,6 and the intravenous sedation and pain relief generally required for colonoscopy are also
associated with cardiovascular and respiratory complications.7 Moreover, patients who have been sedated
are unable to return to work, operate machinery, drive a vehicle or make important decisions for 24 hours
after the procedure.8,9 Older patients or patients with comorbidities are at increased risk of complications and
are also less likely to tolerate the purgative full bowel preparation that is required to cleanse the colon prior
to colonoscopy.10,11 The bowel preparation required for colonoscopy is often the part of this procedure that
patients find most difficult,12 and failure to complete it results in loss of procedural accuracy.10,13,14 There is
also a small miss rate of colonoscopy for colorectal neoplasia, as demonstrated by tandem colonoscopy
studies.15
Radiological whole-colon investigations
The currently available radiological tests for imaging the large bowel include barium enema and CT
colonography. These tests are recommended by NICE for use as alternatives to colonoscopy for the first-line
investigation of older patients who are deemed to be at greater risk of complications – particularly those
associated with sedation – for those who are unwilling to undergo colonoscopy or for whom a colonoscopy
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is deemed not possible.16 In general, however, radiological imaging diagnostics are limited because further
endoscopic investigation is required to collect biopsy specimens and/or remove suspicious lesions in the
event that these are detected.
Barium enema
During this procedure, an enema containing barium suspension is passed through the bowel while the patient
is positioned to facilitate the distribution of the enema throughout the colon. A series of radiographs are
taken with the patient in a number of positions to ensure the adequate visualisation of the entire colorectal
tract. Barium enema has the benefit over colonoscopy of improved safety17 and, although the bowel must also
be prepared, sedation is not required. The diagnostic utility of barium enema is limited by its poor sensitivity.
Current NICE guidelines recommend that barium enema is offered after an incomplete colonoscopy and in
combination with FS for patients with major comorbidity as an alternative to colonoscopy.3 Barium enema is
being replaced by CT colonography when local facilities and expertise are available.
Computerised tomography colonography
Computerised tomography colonography is a relatively new technology for examining the entire colorectum.
During this procedure, two- and three-dimensional images of the colorectal tract are produced. As with
conventional colonoscopy, the patient must still undergo bowel preparation except when faecal tagging is
used, during which a contrast reagent is orally administered; however, no sedation is required for the
procedure. CT colonography is less invasive than colonoscopy and has an improved safety profile.18,19 There is
evidence that patient acceptability for CT colonography may be higher than that for colonoscopy, although
this is not conclusive.20–22 The sensitivity of CT colonography is comparable with that of colonoscopy and
higher than that of barium enema.18,23 CT colonography can detect extracolonic lesions/abnormalities, which
can be useful in patients with vague abdominal symptoms.19 However, many extracolonic abnormalities are
incidental findings of benign origin that, nonetheless, prompt further diagnostic investigations, potentially
exposing the patient to further risk and incurring additional costs.18,24 The sensitivity of CT colonography for
CRC in comparison with colonoscopy has been estimated at 96% in a systematic review.25 In the Special
Interest Group in Gastrointestinal and Abdominal Radiology (SIGGAR) trial, the detection rate of CRC and
large polyps was considerably higher in the trial arm that received CT colonography than in the arm that
received barium enema.18
Alternative to whole-colon investigation: flexible sigmoidoscopy
Flexible sigmoidoscopy is an endoscopic procedure that is used to examine the distal colon and rectum.
Isolated lesions in the proximal colon therefore go undetected with FS, unless a distal lesion is present that
warrants a subsequent whole-colon investigation (WCI).
Flexible sigmoidoscopy can offer both clinical and resource use benefits over WCI. FS is a safer, quicker
procedure than colonoscopy, and intravenous sedation or pain relief is not typically required, which makes
this procedure potentially more appropriate for patients at a higher risk of sedation-related complications,
and also means that the patient can generally return to normal activities immediately.26,27 The lack of need
for sedation removes the requirement for (1) recovery time in the endoscopy unit, (2) the patient to be
accompanied home and (3) the patient to refrain from driving or operating machinery for 24 hours, as is
necessary with sedation. Bowel preparation is more straightforward for FS than for WCI, as it can be
achieved with an enema alone (either self-administered or administered by a health-care professional).26
As with colonoscopy, biopsy tissue and small polyps can be removed during the procedure, although
limited bowel preparation generally means that patients with larger lesions are referred for subsequent
colonoscopy. Another advantage of FS is that it is a less complicated and less risky procedure than
colonoscopy and can be carried out by an appropriately trained nurse specialist.28
It has been suggested that there is scope within the NHS to reduce the diagnostic burden for patients and
endoscopy services by implementing clinical protocols which incorporate the selective use of FS, in place
of WCI, for the initial investigation of patients with symptoms suggestive of distal CRC.29–33 For WCI to be
avoided in favour of FS, diagnostic protocols using FS for first-line investigation must be able to demonstrate
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favourable risk–benefit profiles, in which the benefits of this less invasive procedure are balanced against
the risk of a missed diagnosis of proximal cancer.34–36 The use of such protocols is likely to be most relevant
in clinical practice for which the clinical index of suspicion for proximal colon cancer is low, for example
when patient and symptom profiles favour a diagnosis of distal CRC.33,37
Prevalence of cancers in the proximal versus the distal colorectum
Up to 60% of CRCs diagnosed are in the distal colorectum.38–40 The proportion of CRCs that are diagnosed
at sites in the proximal colon increases with age in both men and women,40,41 although this effect is more
pronounced in women.41 More patients with proximal cancer present as an emergency (i.e. with intestinal
obstruction)42,43 or with iron deficiency anaemia (IDA) and are referred directly to IDA clinics for gastroscopy
and colonoscopy.
Colorectal cancer symptoms and signs
Identifying CRC as a cause of symptoms in a patient presenting to primary care is problematic.44,45 The clinical
features commonly associated with this disease, such as a change in bowel habit (CIBH), rectal bleeding,
abdominal pain, weight loss and anaemia, are also common in the general population and are not specific to
CRC.46,47 Most often, these symptoms will be the result of other, more common conditions with a typically
benign clinical course (e.g. irritable bowel syndrome and haemorrhoids) or, less frequently, more serious
conditions such as inflammatory bowel disease (ulcerative colitis or Crohn’s disease).48,49 Accordingly, the
positive predictive values for many features suggestive of CRC in patients presenting to primary care are
relatively low.44,50 For rectal bleeding and abdominal pain in isolation, the positive predictive values reported
by NICE are 5% and 2%, respectively.46 Evidence suggests that positive predictive values for common
symptoms and signs increase with age and can be higher when features are combined.46,48–51 In patients
referred by their general practitioner (GP) to hospital, positive predictive values for these features are
increased; for example, the positive predictive value for rectal bleeding rises to 5–7% in the secondary
care setting.49
Symptoms suggestive of distal colorectal cancer
Cancers in the proximal and distal colorectum frequently present with different symptom profiles.37,52,53
The majority of CRCs detected in patients with rectal bleeding alone, when the blood is bright red in
colour, are located in parts of the colorectum distal to the splenic flexure.37,53–57 The sensitivity of rectal
bleeding for proximal lesions has been shown to be higher in elderly patients (those aged ≥ 80 years)58 or
when bleeding is severe.54 A CIBH with rectal bleeding is also associated with distal CRC,29 but it is less
clear whether or not a CIBH without rectal bleeding can be used to distinguish distal from proximal CRC.35
Symptoms and signs suggestive of proximal colon cancer
Cancers in the proximal colon are, in general, less likely to present with overt symptoms such as rectal
bleeding.16,52,58–60 IDA, with or without a palpable abdominal mass, is the most distinguishing clinical
feature of proximal colon cancer.16,31,33,52 Another symptom associated with a proximal colon cancer
diagnosis is unexplained weight loss.53 Weight loss, similar to IDA and abdominal mass, could be
symptomatic of more advanced disease16 and might be related to the observation by some that proximal
disease is often diagnosed at a more advanced stage.61,62
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The association between anaemia and proximal colon cancer
Anaemia is a condition in which a person has too few red blood cells, or the oxygen-carrying capacity of
their red blood cells is diminished, to the extent that physiological needs are not met.63 Iron deficiency,
resulting for example from chronic blood loss, is the most common cause of anaemia and leads to IDA, in
which iron stores are depleted and red blood cell production is accordingly compromised.63,64 Decreased
serum ferritin in the presence of low haemoglobin (Hb) and mean corpuscular volume (MCV) is most reliable
for the diagnosis of IDA.64 Blood loss from the gastrointestinal (GI) tract is the most common cause of IDA in
postmenopausal women and in adult men, and in approximately 5–10% of cases IDA is caused by colonic
neoplasia.65 Proximal colon cancer in particular is likely to manifest clinically with the consequences of ‘silent’
GI blood loss such as IDA,37,56 which has been reported to be present in up to 75% of patients with proximal
colon cancer.56,60,66,67 Hb levels are generally lower in those with proximal colon cancer than in those with
distal cancer,61,68 although there is evidence to suggest that Hb levels in a significant proportion of patients
with proximal cancer are higher than locally and nationally defined diagnostic thresholds.68 Thus, the
diagnostic accuracy of anaemia for proximal colon cancer in clinical practice is likely to be influenced by
laboratory thresholds68 and by which haematological parameters are used to determine anaemia status.61
Similarly, the interpretation of clinical studies investigating the diagnostic value of anaemia for CRC by
subsite is hampered by variations in the thresholds and haematological parameters used.
Tailoring initial investigations for suspected colorectal cancers
based on clinical features
Whether or not the reported differences in the symptom profiles of proximal and distal CRCs can be used
to adequately distinguish which patients are so unlikely to have proximal colon cancer that they are
suitable for investigation by FS alone has been the subject of limited research in the UK health-care setting.
A prospective cohort study by Thompson et al.33 of 16,433 consecutive patients aimed to identify patient
groups, based on presenting clinical features, who were most likely to benefit from WCI for investigation of
CRC and which patients could safely be examined by FS because their risk of having a proximal cancer was
so low. The patients included in this study had been referred by their GP to the colorectal clinic at St Mary’s
Hospital, Portsmouth (and two peripheral hospitals), southern England, between 1986 and 2001. In this
patient cohort, 815 (86.2%) out of 946 CRCs were located in the distal colorectum (and, therefore, possible
to detect at FS). This percentage rose to 95.3% (750/787) in patients who did not have IDA or a palpable
abdominal mass, which represented 96.3% (15,829/16,433) of all patients in this cohort. Although 4.7%
(37/787) of CRCs diagnosed in patients without IDA and/or an abdominal mass were proximal, only 2.2%
(17/787) would have been missed with FS as a first-line investigation because there was no additional
indication for WCI, such as symptoms suggestive of obstruction or neoplasia detected by FS.
A retrospective cohort study published in 2010 similarly sought to identify features that were predictive
of CRC anatomical site from the endoscopy and pathology records of 153 patients diagnosed with CRC
between April 2005 and March 2006.31 The findings of this study also supported the tailoring of initial
investigations. In patients with CRC, distal lesions were associated with a CIBH and rectal bleeding. No
patients with rectal bleeding alone had a proximal cancer31 and proximal disease was associated with
anaemia (defined by low Hb level). A total of 88 (70%) out of 126 CRCs (the subset diagnosed in the
outpatient setting) diagnosed in this cohort were in the distal colorectum. The initial diagnostic tool used
to investigate the majority of patients with CRC diagnoses was colonoscopy; only 11% of patients were
initially investigated by FS, compared with 50% initially investigated by colonoscopy.31 In a response to this
study, other authors carried out an audit of 835 colonoscopies performed at their London hospital.30 In this
audit, there were 177 CRC diagnoses between January 2008 and December 2009, and 45 (25%) of these
were proximal colon cancers.30 No patient who had presented with rectal bleeding or a CIBH alone was
subsequently diagnosed with an isolated proximal cancer (i.e. without a synchronous distal cancer).30
There have been other efforts to estimate proximal colon cancer miss rates for symptom-based tailoring of
initial investigations. For the most part, these have been retrospective analyses of patients presenting
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through urgent 2-week wait referral pathways in England for the evaluation of symptoms suggestive of
CRC.29,32,34–36 In an analysis of presenting symptoms in 2-week wait patients with proximal cancer, only
3.4% (7/206) of patients with a CIBH and/or rectal bleeding would have had their proximal cancer missed
if FS had been the only investigation.29 A lower miss rate was calculated in a separate study of patients
with distal symptoms referred to a rapid access colorectal clinic. Two (0.24%) proximal cancers were
diagnosed in patients referred with distal symptoms in isolation after a cancer-free FS; however, the
authors were not explicit as to whether or not there were any other indications for WCI in these patients.32
Others have reported higher miss rates for proximal cancers and have suggested that FS is not an
appropriate first-line investigation for patients with symptoms suggestive of CRC.34,36 For example, Bhangu
et al.34 found that in a cohort of 1725 patients presenting at a 2-week wait clinic, 15.3% (13/85) of cancers
in those presenting without IDA and/or an abdominal mass were proximal and would have been missed by
FS.34 However, the number of patients with proximal cancer who also had other criteria that would have
warranted WCI after FS under current guidelines and standard of care was not reported and, notably,
neither was the number of proximal cancers that were associated with synchronous distal lesions.34
All of the studies described were either undertaken at single sites or in small numbers of patients, which
limits the generalisability of their findings to the wider symptomatic population presenting to secondary care.
National clinical guidelines for symptom-based tailoring of
diagnostic investigations for suspected colorectal cancer
There is a lack of consensus in national clinical guidelines regarding the requirement for WCI to investigate
symptoms suggestive of CRC. Some UK organisations (detailed in the following paragraphs) have made
explicit reference to the use of symptom-based tailoring of investigations and have recommended
substitution of WCI with FS in certain scenarios, while others have not. This has probably had an impact on
the implementation of symptom-driven FS protocols at a local level leading to variations in practice.29,32,33,35,36
A cancer service recommendation was published by NICE in 2004,16 which stated that FS is an appropriate
initial investigation for most patients with bowel symptoms, such as a CIBH and rectal bleeding, given that
these symptoms are indicative of lesions in the distal colon and rectum. This publication also stated that
WCI is necessary when the patient is deemed at risk of proximal disease because of risk factors/clinical
features such as older age, an abdominal mass, IDA, abdominal pain and loss of appetite and weight.16
In the 2011 NICE clinical guideline3 for the diagnosis and management of CRC in secondary care, no
recommendations were made for the tailoring of diagnostic investigations based on symptoms as
predictors of CRC subsite. In patients referred to secondary care with suspected CRC, these guidelines
recommend colonoscopy, except for patients with major comorbidity, for whom FS followed by barium
enema was recommended.3 The Scottish Intercollegiate Guidelines Network69 published recommendations
pertaining to the diagnosis of suspected CRC in 2011 (recommendation 126); these give guidance
concerning the tailoring of investigations of symptoms and clinical features suggestive of large bowel
pathology (including CRC), based on age and symptoms. They recommend that FS may be an appropriate
investigation for patients with rectal bleeding alone who are aged < 50 years. However, when CRC is
suspected, the recommendation is for visualisation of the whole large bowel.69
Guidelines produced by the Association of Coloproctology of Great Britain and Ireland (ACPGBI) in 2007
are clearer in their recommendation for tailoring of CRC investigations based on symptoms.59 These
guidelines state that the majority of patients presenting with rectal bleeding and/or a CIBH and no other
significant risk factors can be examined with FS.59 The reasons for mandatory WCI listed in the ACPGBI
guidelines are an abdominal mass, severe symptoms, a positive faecal occult blood test (FOBt) or strong
family history.59
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In 2011, the British Society for Gastroenterology, the ACPGBI and the Association of Upper Gastrointestinal
Surgeons of Great Britain and Ireland made a joint multisociety position statement on the indications for
diagnostic lower GI endoscopy, which stated that symptoms suggestive of CRC, including persistent rectal
bleeding and/or a CIBH, blood in the stool and IDA, are indications for diagnostic colonoscopy. However,
clinical indications for FS included those < 40 years of age with persistent and/or recurrent bleeding
and/or a CIBH.70
Study rationale
It is likely that the conflicting evidence about whether or not FS is adequate as an initial investigation for
certain symptoms/symptom combinations suggestive of CRC, and the lack of consensus in clinical
guidelines, has affected protocol implementation at the local level.29,32,34,71 There have been calls for further
clarity in this area, particularly in relation to diagnostic protocols for patients presenting with bowel
symptoms alone without IDA and/or a palpable abdominal mass.32,34 In 2011, we proposed the Symptoms
of Colorectal Cancer Evaluation Research (SOCCER) study as an add-on study to the SIGGAR randomised
controlled trials.19 The SIGGAR trials had examined the diagnostic accuracy of CT colonography compared
with colonoscopy or barium enema in patients with symptoms suggestive of CRC.18,23 The SOCCER study
was proposed in order to further contribute to the evidence base with respect to the predictive value of
symptoms for CRC by subsite. In particular, it was designed to investigate whether or not the findings of the
previous study by Thompson et al.33 could be validated in a multicentre setting.
Aims and objectives
Primary objective
The primary objective of the SOCCER study was to investigate the link between patients’ symptoms at
presentation and the risk of cancer in the proximal colon to determine whether or not there are particular
symptoms or symptom combinations which indicate that a patient could be adequately cared for by a
distal colorectum examination (FS) rather than a more extensive WCI. The primary outcome of the SOCCER
study was the diagnostic yield of CRC (proximal/distal) within 3 years of presentation at clinic, by
symptoms at presentation.
Secondary objectives
The secondary objectives of the SOCCER study were to:
l measure the prevalence of proximal and distal CRC in referred patients presenting with symptoms
suggestive of CRC
l determine the number needed to be examined to diagnose one distal cancer, by symptoms
at presentation
l determine the number needed to be examined to diagnose one proximal cancer, by symptoms
at presentation
l determine the miss rate of CRC after FS
l determine hypothetical proximal CRC miss rates if only patients with certain symptoms or combinations
of symptoms are sent for WCI.
Study design and setting
This was a retrospective analysis of prospectively collected data from a cohort of patients who had been
referred to 21 hospitals between 2004 and 2007, with symptoms or signs suggestive of CRC, and who
had been assessed as potentially eligible for the SIGGAR randomised controlled trials.18,19,23
INTRODUCTION
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Chapter 2 Methods
The SOCCER study was proposed as a follow-on study from the SIGGAR multicentre randomisedcontrolled trials.18,19,23 The SOCCER study is a retrospective analysis of a cohort of patients referred to
secondary care who were assessed as potentially eligible for the SIGGAR trials, and includes patients
regardless of whether or not they had been subsequently randomised. This approach was used to enhance
the generalisability of the SOCCER study findings relating to symptoms at presentation, and subsequent
cancer diagnosis, to the wider secondary care population. The clinical trial report for the SIGGAR trials,
which contains information pertaining to trial design and full methodology, has been published elsewhere.19
Methodology relevant to the SOCCER study cohort and analyses will be presented in this report. The
reporting of this study is in accordance with the Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) guidelines.72
Research governance and ethics arrangements
The SIGGAR trials were registered in the International Standard Randomised Controlled Trial Number
registry under ISRCTN95152621. Imperial College London was the nominated sponsor for the SIGGAR and
SOCCER studies. The research governance procedures in place at Imperial College London ensured that all
appropriate regulations and guidelines were followed.
A study steering committee was convened to provide independent oversight of the SOCCER study and
expert advice on aspects of the study. This committee also included a patient representative who provided
input on study plans from the patient perspective.
Ethics approval and permission to use patient data without consent
Ethics approval for the SIGGAR randomised controlled trials was obtained from the Northern and Yorkshire
Multi-Centre Research Ethics Committee on 15 January 2004 and, subsequently, from individual participating
centres. Research ethics approval for the SOCCER study was granted as an extension to the SIGGAR
randomised controlled trials by the North East (York) National Research Ethics Service. The SOCCER study was
also granted Section 251 support under the National Health Service Act 200673 for the processing of patient
identifiable information without consent [references ECC 5–04(E) 2011 and 14/CAG/1043]. To comply with
the conditions of Section 251 support, the Cancer Screening and Prevention Research Group at Imperial
College London (responsible for all aspects of trial and data management for this study) assessed its data
handling procedures against Department of Health information governance standards. The Cancer Screening
and Prevention Research Group holds an Information Governance toolkit to demonstrate compliance with
these standards.74
Recruitment
Selection of participating hospitals
Patients were recruited to the SIGGAR trials from hospital trusts in which a radiologist member of SIGGAR
had expressed a prior interest in participating. Centres were expected to have an established and efficient
fast-track referral system for patients with suspected CRC (usually an identified diagnostic clinic) to
facilitate recruitment, and a named colorectal nurse specialist or researcher who would take responsibility
for recruitment.
The final 21 NHS hospitals were selected via a ‘sham randomisation’ that identified centres likely to
achieve a minimum monthly recruitment target (at least 18 patients).23 These 21 hospital centres included
teaching and general hospitals and were distributed across England (see Appendix 1).
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Patients who were considered potentially eligible for the SIGGAR trials were considered eligible for the
SOCCER study, irrespective of whether or not they were randomised, unless they met the SOCCER study
exclusion criteria.
SIGGAR trial eligibility assessment
Patients were assessed for eligibility for the SIGGAR trials between March 2004 and December 2007.
Consecutive potentially eligible patients were identified by colorectal nurse specialists, research nurses
or radiographers at these centres from CRC and gastroenterology outpatient clinics (including fast-track
CRC clinics) and procedural lists (endoscopy and radiology). Patients who met the following SIGGAR trials
inclusion criteria, and did not meet the exclusion criteria were considered potentially eligible for inclusion in
the SOCCER study.
SIGGAR trials inclusion criteria
l Had been referred to hospital for symptoms or signs suggestive of CRC.
l Were aged ≥ 55 years.
l Were clinically judged to need a WCI.
l Were clinically judged as fit to undergo full bowel preparation.
SIGGAR trials exclusion criteria
l Had a known genetic predisposition to cancer, for example familial adenomatous polyposis or
hereditary non-polyposis CRC.
l Had a known diagnosis of ulcerative colitis or Crohn’s disease.
l Had undergone a WCI in the previous 6 months.
l Had been referred for a WCI to follow up a previously diagnosed CRC.
SOCCER study exclusion criteria
Patients were randomised during the SIGGAR trials (CT colonography vs. colonoscopy or CT colonography
vs. barium enema) only if they met eligibility criteria and had given informed consent, and if a consultant
had consented to their participation. Some patients who were potentially eligible were, therefore, not
randomised during the SIGGAR trials. These patients were included in the SOCCER study analysis unless
they fulfilled the following exclusion criteria:
l declined consent
l gave consent and were randomised but subsequently dissented
l were judged unable to give informed consent
l had no symptoms recorded at presentation
l were untraceable for follow-up CRC diagnoses through the Health and Social Care Information
Centre (HSCIC)
l had a duplicate study record.
Data collection
Patient data used in the SOCCER study were sourced from the SIGGAR trials and additional data were
obtained from hospital records. All data were held in a de-identified format in a separate SOCCER
study database.
Baseline characteristics
Patient baseline characteristics were collected when patients were originally assessed for eligibility for the
SIGGAR trials, and data were collected for both randomised and non-randomised patients. This information
METHODS
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had been recorded on the bespoke SIGGAR trials pro forma and included patient age, sex, date of referral,
the urgency of the referral (‘2-week wait’, ‘urgent’, ‘soon’ or ‘routine’), the referral route, the diagnostic
investigations requested, the outpatient clinic type (if applicable), other relevant diagnoses and whether or
not the patient had initially been investigated by FS. For randomised patients, details of the main SIGGAR
trial interventions (barium enema, CT colonography and colonoscopy) and outpatient appointments were
also recorded on the trial pro forma.
Symptoms and clinical signs
Clinical features at presentation were recorded for potentially eligible patients at baseline during eligibility
assessment for the SIGGAR trials. The SIGGAR trials pro forma contained tick boxes to record symptoms
and clinical signs under ‘details/reason for referral’. Tick boxes were included for ‘rectal bleeding’,
‘abdominal pain’, ‘anaemia’, ‘weight loss’, ‘CIBH’ and ‘positive FOBt’. A free-text field to record additional
symptoms was also included on the pro forma. Entries in the free-text field were manually coded by the
trial team for use in the analysis. They were categorised into ‘abdominal mass’, ‘bloating/flatulence’,
‘tiredness/weakness’, ‘anal symptoms’, ‘nausea/vomiting’, ‘back pain’, ‘upper GI symptoms’, ‘rectal mass’,
‘family history’, ‘history of polyps’, ‘presence of cancer antibodies’, ‘elevated C-reactive protein’ and ‘liver
problems’. A second free-text field to record the details of the CIBH was also included on the pro forma
and was manually coded and categorised to ‘looser and/or more frequent’, ‘harder and/or less frequent’,
‘variable’ or ‘unspecified’.
Data pertaining to clinical features at presentation were also sourced from hospital records. Radiology,
endoscopy and pathology records were requested for patients in the SOCCER study cohort and were
interrogated for information concerning symptoms/clinical signs (specifically abdominal mass, rectal
bleeding, abdominal pain, weight loss, a CIBH and rectal mass). Relevant data were extracted from text
fields. For further details see Data extraction.
Anaemia
Anaemia and IDA are clinical signs that have been associated with proximal colon cancer in previous
clinical studies33,56 and were therefore of key importance to the SOCCER study. Iron deficiency is the most
common cause of anaemia and reflects more severe stages of the disease, when the body is no longer
able to replenish iron stores.64 Decreased MCV (microcytic anaemia) is often assumed to result from iron
deficiency but is relatively non-specific for IDA;64 nonetheless, decreased MCV can be diagnostically useful
in the investigation of GI causes of iron deficiency,65 for example when serum ferritin levels are not
available. However, decreased serum ferritin levels are the most reliable sign for the diagnosis of IDA.64
Owing to the significance to our study of anaemia status, we ideally would have had data on full blood
counts for all patients in order to apply a uniform definition of anaemia and consistently classify the
anaemia status of each patient based on their blood test results. Although a tick box for anaemia as a
reason for referral had been included on the SIGGAR trials pro forma, the classification of anaemia was
not necessarily consistent between hospitals. Therefore, we separated patients into those with blood test
data and those without.
For patients for whom blood test data were available, we used laboratory data to confirm anaemia and
excluded the tick box from our definition of anaemia. For these patients, anaemia status at presentation
was determined from blood tests taken within 6 months before the date of referral (in the SIGGAR trials)
and 3 months after. For patients with a diagnosis of CRC, any blood tests dated on or after the date of
diagnosis were excluded. Blood test parameters [Hb level (g/dl), MCV (fl) and serum ferritin (µg/l)] were
collected from hospital haematology databases (for further details see Data Extraction). When multiple
results for a parameter were available for an individual patient, the lowest recorded value (within the
relevant time period) was selected.
We considered four different definitions of anaemia: ‘broad anaemia’, ‘strict anaemia’, ‘broad IDA’ and
‘strict IDA’. Broad anaemia was defined solely by Hb level: < 13 g/dl in males and < 12 g/dl in females.
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Strict anaemia was defined as a Hb level of < 11 g/dl in males and < 10 g/dl in females, or a Hb level of
≥ 11 g/dl but < 13 g/dl in males or ≥ 10 g/dl but < 12 g/dl in females accompanied by microcytosis (MCV
< 80 fl/cell) or low ferritin (< 20 µg/l). Broad IDA was defined as a Hb level of < 13 g/dl in males and < 12 g/dl
in females accompanied by microcytosis (MCV < 80 fl/cell) or low ferritin (< 20 µg/l) and strict IDA was
defined as a Hb level of < 13 g/dl in males and < 12 g/dl in females accompanied by low ferritin (< 20 µg/l).
For patients without blood test data, in the absence of any available full blood counts, we used the
anaemia tick box on the SIGGAR trials pro forma to define the presence or absence of anaemia. In the
analysis of the overall SOCCER study cohort, anaemia was defined as a Hb level of < 13 g/dl in men or
< 12 g/dl in women for patients with blood test data and by using the anaemia tick box on the pro forma
for patients without blood test data.
Flexible sigmoidoscopy
Details of FS procedures performed at the time of referral had been recorded on a separate pro forma
during the SIGGAR trials and included room entry and exit times; procedure start and stop times; overall
assessment of the examination by the endoscopist (‘very easy’, ‘quite easy’, ‘quite difficult’ or ‘very
difficult’); assessment of bowel preparation quality by the endoscopist (‘excellent’, ‘good’, ‘adequate’ or
‘poor’); the segment of the colon reached and reasons (if any) the examination could not be completed;
overall findings and details of polyps, cancers or biopsies and diverticula (with a severity rating of ‘none’,
‘mild’, ‘moderate’ or ‘severe’); and adverse events occurring during the procedure. Unfortunately, during
scrutiny of these records, it was discovered that in many cases the information included had been taken
from the electronic endoscopy record and that many items were missing.
Data extraction
Additional pathology, endoscopy, radiology and haematology data were collected from the relevant
hospital databases for the SOCCER study patient cohort. When possible, data were bulk extracted; when
this was not possible, data were extracted manually, either by staff at participating hospitals or by
members of the study team who had been granted permission to do so.
A few databases at participating centres had reporting systems that permitted bulk extraction of the data
according to specific criteria. When possible, data were extracted with the help of hospital staff who were
familiar with the systems. For most hospital databases, the application interface was not designed for bulk
data extraction, so acquiring and processing the data was complex and a number of problems were
encountered; for example:
l When the maintenance and support of the hospital databases had been outsourced to the database
manufacturers, often only the manufacturers could help with extracting the data or by writing software
enabling the study programmer to do so.
l Some of the data were held on legacy systems; therefore, specialist support was required to extract
data from these systems.
l Information technology staff at the hospitals sometimes had to restore archived data temporarily so
that they could be extracted.
l Most hospitals had replaced databases over the intervening years and, therefore, some data were
overlapping or were duplicated (e.g. records for the same patient were found on more than
one system).
l The data outputs from these databases were in a combination of structured and unstructured formats.
Structured data could be cleaned easily and converted into a standardised format for uploading. In the
case of unstructured data (usually large text fields), bespoke programs had to be written to extract,
clean and convert the data into a suitable format.
METHODS
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Manually collected data
Data were collected manually in the following scenarios.
l The hospital did not have the facilities or specialists to bulk extract the data for us.
l The quoted cost for bulk extracting the data obtained from the suppliers of the system was excessive,
making manual data collection more cost-effective.
l It was possible to bulk extract the data only from a data warehouse/reporting system (not the main
databases in which the raw data were held) and our findings showed that the data warehouse was not
always up to date. In this scenario we collected the data manually from the applications that were
linked to the main databases.
l The hospital was unable to find specialists to help with bulk extraction within our required time frame,
so we manually collected the data in order to meet our data collection deadlines.
l Some hospitals were able to extract the type of test/examination and date but not provide a report.
We used this information to identify the records of interest and narrowed down the task of manual
data collection to the selected records.
l The data were held on legacy systems and the hospital did not have a maintenance contract with the
suppliers, with the result that there was no option but to extract the data manually.
Study researchers visited hospitals to manually collect data in a bespoke Microsoft Access® database (2010,
Microsoft Corporation, Redmond, WA, USA) or spreadsheet which included patient study numbers. Patient
identifiers from the SIGGAR trials were held at hospitals and were used to search for patients on hospital
databases. De-identified data were returned to the study team, and the study programmer cleaned and
uploaded it to a master SOCCER Oracle database (Oracle Database 11g Enterprise Edition, Oracle
Corporation, Redwood Shores, CA, USA).
Data handling and quality assurance
The SOCCER database was created to store data in a standardised, structured format using a schema
structure similar to the SIGGAR database. To facilitate statistical analysis, the data were classified into
quantitative and qualitative variables, ensuring that data from different hospitals were classified in the
same way as in the SIGGAR database, as there was wide variation in the raw data (e.g. field names were
different, some data were coded or semicoded, whereas other data were in free-text fields, and data
types varied).
The study programmer cleaned and uploaded the data from different hospitals into a standard database
schema, and this involved several steps:
l identifying the fields containing information required for the study, taking into account varying field
names, data types and value representations
l extracting information from free-text fields using programming techniques such as ‘regular expressions’
and ‘fuzzy matching’ and translating them into the codes used on the master database
l translating values in the raw data into those used on the master database, if the information was
already in a coded structured format (e.g. converting units for blood tests)
l identifying and consolidating overlapping data and removing any redundancies (e.g. the same
endoscopy or pathology reports extracted from two different systems)
l identifying and correcting errors in the data (e.g. misspellings, different date formats or truncated
data fields)
l requesting missing data (e.g. missing patients, missing time periods, missing procedure types).
A graphical user interface that linked to the SOCCER database was designed, allowing the study
researchers to efficiently read, interpret, check and manually code the endoscopy, pathology and
symptoms data sets. Study researchers interrogated and linked the clinical reports and categorised the data
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in the same way as in the SIGGAR database. Reference data (sometimes referred to as look-up tables)
were used to categorise and define permissible values for data fields on the database. This method
restricted the values to be recorded in a data field, thereby preventing coding errors and also ensuring
uniformity of data from different hospitals. The study researchers systematically reviewed a blinded random
sample of records that had been coded by other study researchers to ensure accuracy and consistency.
Health and Social Care Information Centre colorectal cancer diagnoses
Colorectal cancer diagnoses within 3 years of referral were obtained from the HSCIC. A unique study
number was allocated to all patients during the SIGGAR trials and the same study number was used for
the SOCCER study cohort. This unique study number was used to collect cancer registrations from the
HSCIC through their data linkage service. For patients who had not been randomised in the SIGGAR trials,
participating hospitals provided the HSCIC with patient identifiers (name, date of birth, NHS number, etc.)
to enable data linkage, as identifiers were not held by the central trial office for the non-randomised
cohort. Hospital teams worked under instruction of the central trial team to prepare the data in the
electronic format specified by the HSCIC. When local assistance was not available to collate the data
required by the HSCIC, central trial team staff members were issued with letters of access by the hospitals
concerned and visited sites personally to complete this task. For the cohort of patients who were
randomised in the SIGGAR trials, the HSCIC already held the records and so no new information needed
to be supplied to them. Following data linkage by the HSCIC, the central trial office received cancer
registrations from the HSCIC for the full SOCCER study cohort in a de-identified format for analysis, which
were linked only by study number.
Statistical methods
Sample size
Our original sample size assumed that we would have a total cohort of 8484 patients, in whom 421 distal
cancers and 68 proximal cancers would be diagnosed. The analysis plan presented estimates for the
precision for the estimated sensitivity under specific regimens, with the precision being conditional on the
number of cancers diagnosed. We assumed that under a regimen offering WCI to patients with IDA and/or
an abdominal mass we would detect 470 of the total 489 cancers, giving a sensitivity estimate of 96.1%
with a 95% confidence interval (CI) of 94.0% to 97.6%. Although the final analysed cohort of 7380
patients was smaller than the proposed sample size, the number of cancers diagnosed was greater than
expected, with a total of 429 distal cancers and 127 proximal cancers, thus providing a greater level of
precision than originally estimated.
Primary outcome
The primary outcome was the diagnostic yield of distal or proximal cancer within 3 years of presentation at
clinic, by symptom category at presentation.18,19,23 CRC diagnoses were sourced from the HSCIC and from
patient medical records. For cancers confirmed by a hospital pathology report but without corresponding
verification by HSCIC, the local pathology report was taken as conclusive evidence of cancer. For the
purposes of this study, CRCs included all cancers with International Classification of Diseases and Related
Health Problems, Tenth Edition,75 site codes C18–C21 and with an International Classification of Diseases
for Oncology, Third Edition,76 morphology code of 8000/3, 8010/3, 8070/3, 8123/3, 8140/2, 8140/3,
8144/3, 8210/3, 8261/2, 8261/3, 8263/2, 8263/3, 8480/3, 8481/3, 8490/3, 8510/3 or 8560/3. CRCs were
classified as ‘distal’ if they were located in the anus, rectum, sigmoid colon or descending colon. Cancers
located proximal to the descending colon were classed as ‘proximal’. Synchronous distal and proximal
CRCs were included as separate cancers in the analysis.
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Secondary outcomes
The secondary outcomes were the sensitivity of symptoms and symptom categories for distal and proximal
cancer, the percentage of patients with cancer who had distal CRC by symptom and symptom category,
the number needed to be examined to diagnose one distal or proximal cancer by symptom and symptom
category at presentation, the miss rate for CRC at FS in the subgroup of patients with FS performed at
baseline and the prevalence of proximal and distal CRC in the study cohort.
Analysis
Outcomes were first analysed separately in the cohort with blood test data and the cohort without blood
test data. The findings in the two cohorts were then compared and outcomes analysed in the total
combined cohort.
Sensitivity was calculated as the proportion of CRCs by cancer site (proximal/distal) that were identified by
a particular symptom or symptom combination. Specificity was defined as the proportion of patients
without CRC by cancer site who presented without a particular symptom/symptom combination.
Diagnostic yields were presented as percentages. The number needed to be examined was calculated as
the inverse of the diagnostic yield. Binomial exact 95% CIs were calculated for key outcomes. The
distributions of categorical variables (patient characteristics, referral details, symptoms, signs, indications
and cancer outcomes) were compared between cohorts using Pearson’s chi-squared test or Fisher’s exact
test, as appropriate, and all tests were two-tailed. Comparisons were made between: cohorts with and
without blood test data; men and women; patients with distal cancer and patients with proximal cancer;
and patients with and without FS performed at the time of referral. Data were analysed using Stata
version 13.1 (StataCorp LP, College Station, TX, USA).
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In total, 8484 patients were assessed for eligibility for the SIGGAR trials, of whom 5448 were randomised
to receive one of three interventions (colonoscopy, barium enema or CT colonography) used in the
diagnosis of CRC and 3036 were not randomised (Figure 1; for reasons see Appendix 2).18,19,23
The SOCCER study used data from both randomised and non-randomised patients in the SIGGAR trials. Of
8484 patients, 1104 were excluded from the SOCCER study (see Figure 1). After exclusions, 7380 patients
were included in the final cohort to be analysed.
Given the clinical significance attached to anaemia/IDA in CRC diagnosis, and the differences in national





• Dissented to use of data in future 
   research, n = 936
• Clinician judged patient unable to 
   provide informed consent for use of 
   data in future research, n = 75
• No symptoms/clinical signs recorded 
   at presentation, n = 27
• Duplicate study records, n = 10
• Not traceable with HSCIC, n = 56
FS examination at baseline, n = 1483
No FS examination at baseline, n = 5897













present or not present
FIGURE 1 The SOCCER study profile.
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investigated the influence on study outcomes of varying the anaemia/IDA definition. These analyses were
restricted to those patients for whom laboratory blood test data were available. Of the 7380 patients in
the final SOCCER study cohort, blood test data were available for 4741 (64.2%) (see Figure 1).
Baseline characteristics of SOCCER patients overall and those
with and without laboratory blood test data
Patient demographics and referral details
Overall, in the full cohort of 7380 patients, there were more women (59.0%) than men (Table 1). The
majority of patients were referred via a colorectal outpatient clinic (84.5%). Just over half of all patients
(n = 3976) were referred via the suspected cancer 2-week wait pathway, and a further 18% were
considered ‘urgent’ referrals (n = 1315). Only 12% (n = 915) of patients in the full cohort were
routine referrals.






With blood test data
(N= 4741)
Without blood test data
(N= 2639)
Sex 0.83
Men 3027 (41.0) 1949 (41.1) 1078 (40.8)
Women 4353 (59.0) 2792 (58.9) 1561 (59.2)
Age (years) < 0.001
55–64 2410 (32.7) 1418 (29.9) 992 (37.6)
65–74 2739 (37.1) 1800 (38.0) 939 (35.6)
75–84 1898 (25.7) 1288 (27.2) 610 (23.1)
≥ 85 333 (4.5) 235 (5.0) 98 (3.7)
Route of referral < 0.001
Colorectal surgical
outpatient clinic
6235 (84.5) 3847 (81.1) 2388 (90.5)
Gastroenterology
outpatient clinic
638 (8.6) 493 (10.4) 145 (5.5)
Other outpatient
clinic
50 (0.7) 44 (0.9) 6 (0.2)
Straight to test 396 (5.4) 309 (6.5) 87 (3.3)
Hospital admission 33 (0.4) 26 (0.6) 7 (0.3)
Not recorded 28 (0.4) 22 (0.5) 6 (0.2)
Urgency of referral < 0.001
Two-week wait 3976 (53.9) 2638 (55.6) 1338 (50.7)
Urgent 1315 (17.8) 754 (15.9) 561 (21.3)
Soon 660 (8.9) 410 (8.7) 250 (9.5)
Routine 915 (12.4) 568 (12.0) 347 (13.1)
Not recorded 514 (7.0) 371 (7.8) 143 (5.4)
a p-value for the comparison of the cohort with blood test data with the cohort without blood test data.
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Comparing the patients with and without blood test data available, those with blood test data were
slightly older, less likely to be referred via a colorectal outpatient clinic and more likely to be referred via a
gastroenterology outpatient clinic than patients without blood test data (all p < 0.001). Slightly more
patients in the cohort with blood test data were referred via the 2-week-wait pathway than in the cohort
without blood test data (p < 0.001).
Colorectal cancer symptoms and clinical signs at presentation
Overall, the most common symptom or clinical sign in the full cohort (n = 7380) was a CIBH: this symptom
was reported in > 70% (n = 5382) of all patients (Table 2). Other common features included rectal
bleeding (n = 2773), abdominal pain (n = 2126) and weight loss (n = 1148). Overall, the symptom/clinical
sign profiles of the cohorts with and without blood test data were similar, although there were some
differences. Notably, rectal bleeding and rectal mass were more common in the cohort without blood test
results, but weight loss and tiredness/weakness were more common in the cohort with blood test results.







With blood test data
(N= 4741)
Without blood test data
(N= 2639)
Symptoms
CIBH 5382 (72.9) 3472 (73.2) 1910 (72.4) 0.43
Looser and/or
more frequent
2862 (38.8) 1852 (39.1) 1010 (38.3)
Harder and/or less
frequent
865 (11.7) 583 (12.3) 282 (10.7)
Variable 648 (8.8) 418 (8.8) 230 (8.7)
Unspecified 1007 (13.6) 619 (13.1) 388 (14.7)
Rectal bleeding 2773 (37.6) 1660 (35.0) 1113 (42.2) < 0.001
Abdominal pain 2126 (28.8) 1367 (28.8) 759 (28.8) 0.95
Weight loss 1148 (15.6) 881 (18.6) 267 (10.1) < 0.001
Bloating/flatulence 203 (2.8) 131 (2.8) 72 (2.7) 0.93
Tiredness/weakness 152 (2.1) 114 (2.4) 38 (1.4) 0.005
Anal symptoms 97 (1.3) 56 (1.2) 41 (1.5) 0.18
Nausea/vomiting 44 (0.6) 32 (0.7) 12 (0.4) 0.24
Back pain 13 (0.2) 7 (0.1) 6 (0.2) 0.43
Upper GI symptoms 10 (0.1) 10 (0.2) 0 (0) 0.018
Signs/indications
Abdominal mass 216 (2.9) 140 (3.0) 76 (2.9) 0.86
Rectal mass 165 (2.2) 81 (1.7) 84 (3.2) < 0.001
FOBt positive 113 (1.5) 76 (1.6) 37 (1.4) 0.50
Family history 117 (1.6) 69 (1.5) 48 (1.8) 0.23
History of polyps 23 (0.3) 14 (0.3) 9 (0.3) 0.74
Other signsb 16 (0.2) 11 (0.2) 5 (0.2) 0.71
a p-value for the comparison of the cohort with blood test data with the cohort without blood test data.
b Other signs include the presence of cancer antibodies, elevated C-reactive protein or liver problems.
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Colorectal cancer diagnoses by anatomical subsite
The prevalence of CRC in the whole cohort was 7.5% (Table 3). Overall, distal cancer was diagnosed in
5.8% of patients and proximal cancer was diagnosed in 1.7% of patients. Distal cancer was less common
in the cohort with blood test data than in the cohort without (p < 0.001), whereas proximal cancer was
more common in the cohort with blood test data (p = 0.007).
Anaemia and iron deficiency anaemia
Of the 4741 patients for whom blood test data at presentation were available, serum ferritin results were
available for 1157 (approximately 24%) (Table 4). Among patients for whom ferritin data were available,
low levels of serum ferritin (< 20 µg/l) were reported in approximately 31% (n = 353). MCVs were low
(< 80 fl) in 9.0% (n = 176) of men and 8.2% (n = 229) of women. In total, 31.8% (n = 256) of men and
36.5% (n = 311) of women with low Hb levels (< 13 g/dl for men and < 12 g/dl for women) had either a
low serum ferritin or a low MCV level. Only 1.1% (n = 13) of men and 2.7% (n = 53) of women with
normal Hb also had low serum ferritin or MCV.






With blood test data
(N= 4741)
Without blood test data
(N= 2639)
Total patients with cancer 551b (7.5) 333c (7.0) 218d (8.3) 0.053
Distal cancers
Total patients with distal
cancer
429b (5.8) 240c (5.1) 189d (7.2) < 0.001
Anus 10 (0.1) 6 (0.1) 4 (0.2)
Rectum 210 (2.8) 103 (2.2) 107 (4.1)
Rectosigmoid 57 (0.8) 40 (0.8) 17 (0.6)
Sigmoid colon 146 (2.0) 87 (1.8) 59 (2.2)
Descending colon 8 (0.1) 6 (0.4) 2 (0.1)
Distal colorectum
(no further specification)




127b (1.7) 96c (2.0) 31d (1.2) 0.007
Splenic flexure 9 (0.1) 9 (0.2) 0 (0)
Transverse colon 18 (0.2) 12 (0.3) 6 (0.2)
Hepatic flexure 14 (0.2) 13 (0.3) 1 (0.04)
Ascending colon 36 (0.5) 27 (0.6) 9 (0.3)
Caecum 53 (0.7) 38 (0.8) 15 (0.6)
a p-value for the comparison of the cohort with blood test data with the cohort without blood test data.
b In total, 565 cancers were diagnosed in 551 patients; five patients had both distal and proximal cancer, three patients
had two proximal cancers and six patients had two distal cancers.
c In total, 342 cancers were diagnosed in 333 patients; three patients had both distal and proximal cancer, three patients
had two proximal cancers and three patients had two distal cancers.
d In total, 223 cancers were diagnosed in 218 patients; two patients had both distal and proximal cancer and three
patients had two distal cancers.
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Analyses in patients with blood test data
When applying the broadest definition of anaemia (based on low Hb level alone), > 40% (n = 806) of men
and 30% (n = 853) of women were anaemic (Table 5). The proportions of men and women who were
anaemic decreased as the definitions were tightened to improve specificity for anaemia resulting from
iron deficiency, by either reducing the Hb threshold or introducing MCV and/or serum ferritin into the
diagnostic criteria. The proportions of men and women with anaemia by the stricter definition were
approximately half of those for the broad definition (35.0% vs. 18.5%). Only 12.0% of patients presented
with probable IDA (broad definition IDA) and 6.7% presented with laboratory-confirmed IDA, for which
iron deficiency was confirmed by low serum ferritin.




Men (n= 1949) Women (n= 2792)






Hb ≥ 13 g/dl
(N= 1143,
58.7%)












190 (52.9) 148 (33.1) 155 (13.6) 182 (58.3) 201 (37.2) 281 (14.5)
Result lowa 97 (27.0) 49 (11.0) 6 (0.5) 98 (31.4) 74 (13.7) 29 (1.5)
MCV lowb 132 (36.8) 36 (8.1) 8 (0.7) 119 (38.1) 83 (15.3) 27 (1.4)
Ferritin or
MCV low
184 (51.3) 72 (16.1) 13 (1.1) 179 (57.4) 132 (24.4) 53 (2.7)
Neither ferritin
nor MCV low
175 (48.7) 375 (83.9) 1130 (98.9) 133 (42.6) 409 (75.6) 1886 (97.3)
a Low ferritin defined as < 20 µg/l.
b Low MCV defined as < 80 fl.




n (%)Men (N= 1949) Women (N= 2792)
Anaemia
Broad definition anaemia: Hb level of < 13 g/dl in
men or < 12 g/dl in women
806 (41.4) 853 (30.6) 1659 (35.0)
Strict definition anaemia: Hb level of < 11 g/dl in
men or < 10 g/dl in women, or Hb level of ≥ 11 g/dl
and < 13 g/dl in men or ≥ 10 g/dl and < 12 g/dl in
women accompanied by microcytosis (MCV < 80 fl)
or low ferritin (< 20 µg/l)
431 (22.1) 444 (15.9) 875 (18.5)
IDA
Broad definition IDA: Hb level of < 13 g/dl in
men or < 12 g/dl in women accompanied by
microcytosis (MCV < 80 fl) or low ferritin (< 20 µg/l)
256 (13.1) 311 (11.1) 567 (12.0)
Strict definition IDA: Hb level of < 13 g/dl in men or
< 12 g/dl in women accompanied by low ferritin
(< 20 µg/l)
146 (7.5) 172 (6.2) 318 (6.7)
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Patient demographics and referral details in those with
laboratory blood test data
To enable the consideration of anaemia and IDA clinical features, the analyses were restricted to those 4741
patients for whom blood test data were available, of whom 58.9% (n = 2792) were women (Table 6). Over
one-third (38%; n = 1800) of patients were aged 65–74 years at presentation, with fewer than 5% (n = 235)
aged ≥ 85 years. The proportions of men and women in each age group were similar, and the median age
was 70 years (interquartile range 63–77 years) for both men and women. More than 80% (n = 3847) of
patients were referred to colorectal surgical outpatient clinics and approximately 10% (n = 493) were
referred to gastroenterology outpatient clinics. Over 50% of patients (n = 2638) were referred via the
suspected cancer 2-week wait pathway and a further 16% were ‘urgent’ referrals (n = 754). Only 12%
(n = 568) of patients in the cohort with blood test data were routine referrals.
Colorectal cancer symptoms and clinical signs by sex and age
Clinical features that were more common in women than in men were CIBH (all subtypes with the
exception of harder stools and/or less frequent defecation) (p < 0.001), abdominal pain (p < 0.001) and
abdominal mass (p = 0.029) (Table 7). Rectal bleeding was more common in men than in women
(p < 0.001). Similarly, more men than women presented with anaemia (p < 0.001) and IDA by the broad
definition (p = 0.037).
TABLE 6 Patient demographics and referral details by sex in 4741 patients with blood test data
Characteristic
Sex, n (%)
p-valueMen (N= 1949) Women (N= 2792)
Age (years) 0.10
55–64 551 (28.3) 867 (31.1)
65–74 772 (39.6) 1028 (36.8)
75–84 536 (27.5) 752 (26.9)
≥ 85 90 (4.6) 145 (5.2)
Route of referral 0.50
Colorectal surgical outpatient clinic 1587 (81.4) 2260 (80.9)
Gastroenterology outpatient clinic 199 (10.2) 294 (10.5)
Other outpatient clinic 18 (0.9) 26 (0.9)
Straight to test 128 (6.6) 181 (6.5)
Hospital admission 6 (0.3) 20 (0.7)
Not recorded 11 (0.6) 11 (0.4)
Urgency of referral 0.48
Two-week wait 1076 (55.2) 1562 (56.0)
Urgent 332 (17.0) 422 (15.1)
Soon 165 (8.5) 245 (8.8)
Routine 230 (11.8) 338 (12.1)
Not recorded 146 (7.5) 225 (8.1)
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The proportions of men and women with rectal bleeding or abdominal pain decreased with increasing age
(Table 8). Anaemia was substantially more common in older age groups in both men and women; 73% of
men (n = 66) and more than half of women (n = 83) aged ≥ 85 years were anaemic (broad definition),
compared with 24% of men (n = 131) and 19% of women (n = 161) aged 55–64 years. Similar trends
with age for men and women were observed for all other definitions of anaemia and IDA.
TABLE 7 Symptoms and signs/indications by sex in 4741 patients with blood test data
Symptoms and signs/indications
Sex, n (%)
p-valueMen (N= 1949) Women (N= 2792)
Symptoms
CIBH 1352 (69.4) 2120 (75.9) < 0.001
Looser and/or more frequent 721 (37.0) 1131 (40.5)
Harder and/or less frequent 259 (13.3) 324 (11.6)
Variable 133 (6.8) 285 (10.2)
Unspecified 239 (12.3) 380 (13.6)
Rectal bleeding 744 (38.2) 916 (32.8) < 0.001
Abdominal pain 448 (23.0) 919 (32.9) < 0.001
Weight loss 386 (19.8) 495 (17.7) 0.071
Bloating/flatulence 51 (2.6) 80 (2.9) 0.61
Tiredness/weakness 51 (2.6) 63 (2.3) 0.43
Anal symptoms 23 (1.2) 33 (1.2) 0.99
Nausea/vomiting 8 (0.4) 24 (0.9) 0.072
Back pain 2 (0.1) 5 (0.2) 0.71
Upper GI symptoms 2 (0.1) 8 (0.3) 0.21
Signs/indications
Anaemia
Anaemia (broad)a 806 (41.4) 853 (30.6) < 0.001
Anaemia (strict)b 431 (22.1) 444 (15.9) < 0.001
IDA (broad)c 256 (13.1) 311 (11.1) 0.037
IDA (strict)d 146 (7.5) 172 (6.2) 0.072
Abdominal mass 45 (2.3) 95 (3.4) 0.029
Rectal mass 28 (1.4) 53 (1.9) 0.228
FOBt positive 31 (1.6) 45 (1.6) 0.95
Family history 21 (1.1) 48 (1.7) 0.070
History of polyps 10 (0.5) 4 (0.1) 0.028
Other signse 6 (0.3) 5 (0.2) 0.38
a Anaemia (broad) is defined as a Hb level of < 13 g/dl in men or < 12 g/dl in women.
b Anaemia (strict) is defined as a Hb level of < 11 g/dl in men or < 10 g/dl in women, or a Hb level of ≥ 11 g/dl and
< 13 g/dl in men or ≥ 10 g/dl and < 12 g/dl in women accompanied by microcytosis (MCV of < 80 fl) or low ferritin
(< 20 µg/l).
c IDA (broad) is defined as a Hb level of < 13 g/dl in men or < 12 g/dl in women accompanied by microcytosis
(MCV of < 80 fl) or low ferritin (< 20 µg/l).
d IDA (strict) is defined as a Hb level of < 13 g/dl in men or < 12 g/dl in women accompanied by low ferritin (< 20 µg/l).
e Other signs include the presence of cancer antibodies, elevated C-reactive protein or liver problems.
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CIBH 382 (69.3) 531 (68.8) 365 (68.1) 74 (82.2) 679 (78.3) 795 (77.3) 546 (72.6) 100 (69.0)
Looser and/or
more frequent
238 (43.2) 261 (33.8) 186 (34.7) 36 (40.0) 383 (44.2) 418 (40.7) 288 (38.3) 42 (29.0)
Harder and/or
less frequent
49 (8.9) 104 (13.5) 83 (15.5) 23 (25.6) 79 (9.1) 118 (11.5) 109 (14.5) 18 (12.4)
Variable 26 (4.7) 66 (8.6) 37 (6.9) 4 (4.4) 92 (10.6) 112 (10.9) 65 (8.6) 16 (11.0)
Unspecified 69 (12.5) 100 (12.9) 59 (11.0) 11 (12.2) 125 (14.4) 147 (14.3) 84 (11.2) 24 (16.6)
Rectal bleeding 245 (44.5) 290 (37.6) 184 (34.3) 25 (27.8) 328 (37.8) 338 (32.9) 217 (28.9) 33 (22.8)
Abdominal pain 161 (29.2) 176 (22.8) 103 (19.2) 8 (8.9) 315 (36.3) 357 (34.7) 216 (28.7) 31 (21.4)
Weight loss 99 (18.0) 132 (17.1) 125 (23.3) 30 (33.3) 113 (13.0) 170 (16.5) 182 (24.2) 30 (20.7)
Bloating/flatulence 22 (4.0) 24 (3.1) 4 (0.8) 1 (1.1) 25 (2.9) 32 (3.1) 20 (2.7) 3 (2.1)
Tiredness/weakness 12 (2.2) 21 (2.7) 17 (3.2) 1 (1.1) 10 (1.2) 29 (2.8) 21 (2.8) 2 (2.1)
Anal symptoms 9 (1.6) 10 (1.3) 3 (0.6) 1 (1.1) 10 (1.2) 15 (1.5) 8 (1.1) 0 (0)
Nausea/vomiting 2 (0.4) 2 (0.3) 4 (0.8) 0 (0) 5 (0.6) 9 (0.9) 9 (1.2) 1 (0.7)
Back pain 1 (0.2) 1 (0.1) 0 (0) 0 (0) 1 (0.1) 2 (0.2) 2 (0.3) 0 (0)
Upper GI symptoms 1 (0.2) 1 (0.1) 0 (0) 0 (0) 2 (0.2) 4 (0.4) 1 (0.1) 1 (0.7)
Signs/indications
Anaemia
Anaemia (broad)a 131 (23.8) 314 (40.7) 295 (55.0) 66 (73.3) 161 (18.6) 280 (27.2) 329 (43.7) 83 (57.2)
Anaemia (strict)b 74 (13.4) 164 (21.2) 156 (29.1) 37 (41.1) 86 (9.9) 145 (14.1) 167 (22.2) 46 (31.7)
IDA (broad)c 47 (8.5) 108 (14.0) 79 (14.7) 22 (24.4) 68 (7.8) 105 (10.2) 114 (15.2) 24 (16.6)
IDA (strict)d 27 (4.9) 63 (8.2) 49 (9.1) 7 (7.8) 39 (4.5) 61 (5.9) 58 (7.7) 14 (9.7)
Abdominal mass 12 (2.2) 20 (2.6) 10 (1.9) 3 (3.3) 18 (2.1) 34 (3.3) 27 (3.6) 16 (11.0)
Rectal mass 10 (1.8) 8 (1.0) 8 (1.5) 2 (2.2) 14 (1.6) 14 (1.4) 14 (1.9) 11 (7.6)
FOBt positive 3 (0.5) 13 (1.7) 13 (2.4) 2 (2.2) 13 (1.5) 18 (1.7) 13 (1.7) 1 (0.7)
Family history 8 (1.5) 10 (1.3) 3 (0.6) 0 (0) 23 (2.7) 15 (1.5) 7 (0.9) 3 (2.1)
History of polyps 3 (0.5) 4 (0.5) 3 (0.6) 0 (0) 1 (0.1) 2 (0.2) 1 (0.1) 0 (0)
Other signse 3 (0.5) 0 (0) 3 (0.6) 0 (0) 2 (0.2) 2 (0.2) 1 (0.1) 0 (0)
a Anaemia (broad) is defined as a Hb level of < 13 g/dl in men or < 12 g/dl in women.
b Anaemia (strict) is defined as a Hb level of < 11 g/dl in men or < 10 g/dl in women, or a Hb level of ≥ 11 g/dl and
< 13 g/dl in men or ≥ 10 g/dl and < 12 g/dl in women accompanied by microcytosis (MCV of < 80 fl) or low ferritin
(< 20 µg/l).
c IDA (broad) is defined as a Hb level of < 13 g/dl in men or < 12 g/dl in women accompanied by microcytosis
(MCV of < 80 fl) or low ferritin (< 20 µg/l).
d IDA (strict) is defined as a Hb level of < 13 g/dl in men or < 12 g/dl in women accompanied by low ferritin (< 20 µg/l).
e Other signs include the presence of cancer antibodies, elevated C-reactive protein or liver problems.
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The proportions of patients presenting with a CIBH (all subtypes combined) were also influenced by age;
however, the trends observed for men and women were not the same. A CIBH was more commonly
reported in men aged ≥ 85 years (82.2%) than in men aged 55–64 years (69.3%) but was less common in
older women (69% in those aged ≥ 85 years vs. 78.3% in those aged 55–64 years). The trend in men was
largely a result of the increase in the proportion of men with harder stools and/or less frequent defecation
with increasing age (8.9% in those aged 55–64 years vs. 25.6% in those aged ≥ 85 years), whereas fewer
women reported a CIBH to looser and/or more frequent stools with increasing age (44.2% in those aged
55–64 years vs. 29.0% in those aged ≥ 85 years).
There was evidence of some association between age, gender and the presence of other less common
clinical features, although in many cases the numbers available for analysis by age group were low.
In women, but not in men, the presence of an abdominal mass as a reported clinical sign increased
with increasing age. An abdominal mass was reported by 11.0% of women (n = 16) aged ≥ 85 years,
compared with 2.1% of women (n = 18) aged 55–64 years. Similarly, there was evidence to suggest that a
rectal mass was more commonly reported in older women (7.6% in women aged ≥ 85 years vs. 1.6% in
those aged 55–64 years).
Colorectal cancer symptoms and clinical signs in isolation and in combination
Approximately 95% of patients (n = 4486) presented with between one and three features that are
referral criteria in the NICE 2015 guidelines76 for suspected CRC; just over one-third (n = 1626) presented
with a single NICE criteria symptom/sign (Table 9).
The NICE qualifying features most commonly reported as single symptoms were a CIBH and rectal
bleeding. For NICE criteria signs, between 36% and 43% of patients (depending on the definition used)
presenting with IDA did so in the absence of any other NICE criteria. The proportions of patients
presenting with anaemia/IDA in the absence of other NICE criteria symptoms/signs increased as the
definition used for anaemia became stricter through inclusion of a requirement for iron deficiency.
The majority (67.4%) of the 3472 patients with a CIBH presented with this symptom in combination with
one or two other NICE qualifying features. Similarly, the majority of patients (73.2%) with rectal bleeding
presented with this symptom in combination with one or two other NICE qualifying features. Few patients
with weight loss (1.2%) or abdominal pain (7.9%) presented without additional NICE qualifying features.
Very few patients (n = 16) with features that were non-NICE qualifying presented without additional
NICE criteria.
Patients with NICE qualifying features commonly presented with symptoms in combination with a CIBH,
which probably reflected the high prevalence of this symptom in the cohort (73% overall prevalence)
(Table 10). For instance, > 60% of patients (n = 1022) with rectal bleeding presented with a CIBH.
Patients with anaemia/IDA commonly presented with these signs in combination with a CIBH, rectal
bleeding and weight loss. Sixty per cent (n = 989) of patients with anaemia (broad definition) also had a
CIBH, compared with 37% (n = 119) of patients with IDA (strict definition) (see Table 10).
Patient demographics and referral details in those with colorectal
cancer diagnoses
Distal cancers were more likely to be diagnosed in men and proximal cancers were more likely to be
diagnosed in women (p = 0.013) (Table 11). There were no major differences in subsite diagnoses by
referral route (p = 0.21) or urgency of referral (p = 0.62).
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Number of NICE 2015 guideline symptoms or signs per patienta
0, n (%) 1, n (%) 2, n (%) 3, n (%) 4, n (%) 5, n (%) 6, n (%)
Total 4741 16 (0.3) 1626 (34.3) 1936 (40.8) 923 (19.5) 209 (4.4) 30 (0.6) 1 (0.0)
Symptoms
CIBH 3472 0 (0.0) 903 (26.0) 1522 (43.8) 818 (23.6) 198 (5.7) 30 (0.9) 1 (0.0)
Looser and/or
more frequent
1852 0 (0.0) 521 (28.1) 791 (42.7) 417 (22.5) 107 (5.8) 15 (0.8) 1 (0.1)
Harder and/or less
frequent
583 0 (0.0) 96 (16.5) 267 (45.8) 172 (29.5) 39 (6.7) 9 (1.5) 0 (0.0)
Variable 418 0 (0.0) 111 (26.6) 197 (47.1) 89 (21.3) 20 (4.8) 1 (0.2) 0 (0.0)
Unspecified 619 0 (0.0) 175 (28.3) 267 (43.1) 140 (22.6) 32 (5.2) 5 (0.8) 0 (0.0)
Rectal bleeding 1660 0 (0.0) 286 (17.2) 733 (44.2) 481 (29.0) 137 (8.2) 22 (1.3) 1 (0.1)
Abdominal pain 1367 0 (0.0) 108 (7.9) 629 (46.0) 467 (34.2) 135 (9.9) 27 (2.0) 1 (0.1)
Weight loss 881 0 (0.0) 11 (1.2) 310 (35.2) 379 (43.0) 152 (17.3) 28 (3.2) 1 (0.1)
Bloating/flatulence 131 3 (2.3) 41 (31.3) 57 (43.5) 24 (18.3) 6 (4.6) 0 (0.0) 0 (0.0)
Tiredness/weakness 114 3 (2.6) 16 (14.0) 41 (36.0) 32 (28.1) 18 (15.8) 4 (3.5) 0 (0.0)
Anal symptoms 56 1 (1.8) 23 (41.1) 17 (30.4) 13 (23.2) 2 (3.6) 0 (0.0) 0 (0.0)
Nausea/vomiting 32 0 (0.0) 7 (21.9) 10 (31.3) 12 (37.5) 3 (9.4) 0 (0.0) 0 (0.0)
Back pain 7 0 (0.0) 1 (14.3) 2 (28.6) 3 (42.9) 0 (0.0) 1 (14.3) 0 (0.0)
Upper GI symptoms 10 0 (0.0) 3 (30.0) 4 (40.0) 1 (10.0) 1 (10.0) 1 (10.0) 0 (0.0)
Signs/indications
Anaemia
Anaemia (broad)b 1659 0 (0.0) 307 (18.5) 606 (36.5) 544 (32.8) 173 (10.4) 28 (1.7) 1 (0.1)
Anaemia (strict)c 875 0 (0.0) 243 (27.8) 306 (35.0) 235 (26.9) 78 (8.9) 12 (1.4) 1 (0.1)
IDA (broad)d 567 0 (0.0) 206 (36.3) 181 (31.9) 128 (22.6) 46 (8.1) 5 (0.9) 1 (0.2)
IDA (strict)e 318 0 (0.0) 135 (42.5) 91 (28.6) 69 (21.7) 21 (6.6) 2 (0.6) 0 (0.0)
Abdominal mass 140 0 (0.0) 2 (1.4) 41 (29.3) 53 (37.9) 32 (22.9) 11 (7.9) 1 (0.7)
Rectal mass 81 0 (0.0) 9 (11.1) 31 (38.3) 27 (33.3) 9 (11.1) 5 (6.2) 0 (0.0)
FOBt positive 76 9 (11.8) 32 (42.1) 24 (31.6) 10 (13.2) 1 (1.3) 0 (0.0) 0 (0.0)
Family history 69 1 (1.4) 30 (43.5) 27 (39.1) 8 (11.6) 3 (4.3) 0 (0.0) 0 (0.0)
History of polyps 14 0 (0.0) 6 (42.9) 5 (35.7) 3 (21.4) 0 (0.0) 0 (0.0) 0 (0.0)
Other signsf 11 2 (18.2) 1 (9.1) 4 (36.4) 4 (36.4) 0 (0.0) 0 (0.0) 0 (0.0)
Shading indicates NICE 2015 guideline76 signs/symptoms/indications.
a NICE 2015 guideline signs/symptoms/indications included CIBH, rectal bleeding, abdominal pain, weight loss, anaemia
and an abdominal or a rectal mass without any restriction by age; the broad definition of anaemia was included. Patients
may have had multiple signs/symptoms/indications.
b Anaemia (broad) is defined as a Hb level of < 13 g/dl in men or < 12 g/dl in women.
c Anaemia (strict) is defined as a Hb level of < 11 g/dl in men or < 10 g/dl in women, or a Hb level of ≥ 11 g/dl and < 13 g/dl
in men or ≥ 10 g/dl and < 12 g/dl in women accompanied by microcytosis (MCV of < 80 fl) or low ferritin (< 20 µg/l).
d IDA (broad) is defined as a Hb level of < 13 g/dl in men or < 12 g/dl in women accompanied by microcytosis (MCV of
< 80 fl) or low ferritin (< 20 µg/l).
e IDA (strict) is defined as a Hb level of < 13 g/dl in men or < 12 g/dl in women accompanied by low ferritin (< 20 µg/l).
f Other signs include the presence of cancer antibodies, elevated C-reactive protein or liver problems.
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TABLE 10 Combinations of symptoms and signs/indications in 4741 patients with blood test data
Symptoms and
signs/indications Total, n















CIBH 3472 – 1022 1032 698 989 92 45
Rectal bleeding 1660 1022 – 378 227 501 32 40
Abdominal pain 1367 1032 378 – 261 348 53 10
Weight loss 881 698 227 261 – 398 47 10
Bloating/flatulence 131 107 23 57 27 32 3 2
Tiredness/weakness 114 95 22 38 61 51 16 3
Anal symptoms 56 34 32 11 9 13 1 4
Nausea/vomiting 32 24 5 15 16 14 1 0
Back pain 7 6 3 2 4 3 0 1
Upper GI symptoms 10 9 2 4 3 4 1 0
Signs/indications
Anaemia
Anaemia (broad)b 1659 989 501 348 398 – 68 27
Anaemia (strict)c 875 430 231 153 202 – 34 13
IDA (broad)d 567 238 133 86 116 – 22 5
IDA (strict)e 318 119 69 44 56 – 7 5
Abdominal mass 140 92 32 53 47 68 – 1
Rectal mass 81 45 40 10 10 27 1 –
FOBt positive 76 35 11 18 16 34 0 0
Family history 69 50 29 20 7 12 1 1
History of polyps 14 7 8 4 0 6 0 0
Other signsf 11 8 2 3 5 3 0 0
Shading indicates NICE 201576 guideline signs/symptoms/indications.
a NICE 2015 guideline signs/symptoms/indications included CIBH, rectal bleeding, abdominal pain, weight loss, anaemia
and an abdominal or a rectal mass without any restriction by age; the broad definition of anaemia was included. Patients
may have had multiple signs/symptoms/indications.
b Anaemia (broad) is defined as a Hb level of < 13 g/dl in men or < 12 g/dl in women.
c Anaemia (strict) is defined as a Hb level of < 11 g/dl in men or < 10 g/dl in women, or a Hb level of ≥ 11 g/dl and < 13 g/dl
in men or ≥ 10 g/dl and < 12 g/dl in women accompanied by microcytosis (MCV of < 80 fl) or low ferritin (< 20 µg/l).
d IDA (broad) is defined as a Hb level of < 13 g/dl in men or < 12 g/dl in women accompanied by microcytosis (MCV of
< 80 fl) or low ferritin (< 20 µg/l).
e IDA (strict) is defined as a Hb level of < 13 g/dl in men or < 12 g/dl in women accompanied by low ferritin (< 20 µg/l).
f Other signs include the presence of cancer antibodies, elevated C-reactive protein or liver problems.
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Prevalence of distal colorectal and proximal colon cancers by age and sex
In stratified analyses, there were apparent trends in the prevalence of distal and proximal cancer by age
and sex (Table 12). In women, the prevalence of distal cancer increased with age; 5.5% of women (n = 8)
aged ≥ 85 years were diagnosed with distal cancer, compared with 2.2% of women (n = 19) aged
55–64 years. This trend in distal cancer prevalence by age was less apparent in men; however, distal
cancer was more prevalent in men aged ≥ 65 years than in those aged 55–64 years. The prevalence of
proximal cancer increased with increasing age in both men and women.




p-valueaDistal (N= 240) Proximal (N= 96)
Sex 0.013
Men 145 (60.4) 44 (45.8)
Women 95 (39.6) 52 (54.2)
Age (years) 0.44
55–64 54 (22.5) 14 (14.6)
65–74 91 (37.9) 39 (40.6)
75–84 80 (33.3) 35 (36.5)
≥ 85 15 (6.3) 8 (8.3)
Route of referral 0.21
Colorectal surgical outpatient clinic 198 (82.5) 81 (84.4)
Gastroenterology outpatient clinic 22 (9.2) 10 (10.4)
Other outpatient clinic 3 (1.2) 2 (2.1)
Straight to test 17 (7.1) 2 (2.1)
Hospital admission 0 (0) 1 (1.0)
Urgency of referral 0.62
Two-week wait 169 (70.4) 62 (64.6)
Urgent 29 (12.1) 17 (17.7)
Soon 13 (5.4) 7 (7.3)
Routine 12 (5.0) 5 (5.2)
Not recorded 17 (7.1) 5 (5.2)
a Three patients had both distal and proximal cancer diagnosed and they were excluded from the estimation of the
p-value.
TABLE 12 Colorectal cancers diagnosed in 4741 patients with blood test data by subsite, sex and age group
CRC subsite
Sex, n (%)

























Distal 35 (6.4) 59 (7.6) 44 (8.2) 7 (7.8) 19 (2.2) 32 (3.1) 36 (4.8) 8 (5.5)
Proximal 9 (1.6) 15 (1.9) 17 (3.2) 3 (3.3) 5 (0.6) 24 (2.3) 18 (2.4) 5 (3.4)
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Symptomatic presentation of colorectal cancers by subsite
The symptom that was most commonly associated with distal cancer was a CIBH (Table 13), which was
reported in 71.7% of distal CRC patients either as a single symptom or in combination with other clinical
features. Looser and/or more frequent stools was the most commonly reported CIBH in those with distal
cancer. Rectal bleeding was reported by 64.2% of those with distal cancer (n = 154).
TABLE 13 Symptoms and signs in patients diagnosed with CRCs in 4741 patients with blood test data
Characteristica
Cancer, n (%)
p-valuebDistal (N= 240) Proximal (N= 96)
Symptoms
CIBH 172 (71.7) 52 (54.2) 0.002
Looser and/or more frequent 97 (40.4) 26 (27.1)
Harder and/or less frequent 28 (11.7) 12 (12.5)
Variable 12 (5.0) 5 (5.2)
Unspecified 35 (14.6) 9 (9.4)
Rectal bleeding 154 (64.2) 20 (20.8) < 0.001
Abdominal pain 51 (21.3) 33 (34.4) 0.012
Weight loss 50 (20.8) 24 (25.0) 0.50
Bloating/flatulence 6 (2.5) 3 (3.1) 0.73
Tiredness/weakness 7 (2.9) 4 (4.2) 0.51
Anal symptoms 1 (0.4) 0 (0) 0.99
Nausea/vomiting 3 (1.2) 0 (0) 0.56
Signs/indications
Anaemia
Anaemia (broad)c 106 (44.2) 77 (80.2) < 0.001
Anaemia (strict)d 52 (21.7) 60 (62.5) < 0.001
IDA (broad)e 36 (15.0) 48 (50.0) < 0.001
IDA (strict)f 12 (5.0) 20 (20.8) < 0.001
Abdominal mass 10 (4.2) 8 (8.3) 0.17
Rectal mass 15 (6.3) 0 (0) 0.008
FOBt positive 6 (2.5) 2 (2.1) 0.99
Family history 3 (1.2) 2 (2.1) 0.62
History of polyps 0 (0) 1 (1.0) 0.28
Shading indicates NICE 2015 guideline76 signs/symptoms/indications.
a Back pain, upper GI symptoms and other signs were excluded from this table as no patients diagnosed with CRC
presented with these symptoms or signs.
b Three patients had both distal and proximal cancer diagnosed and they were excluded from the estimation of the
p-value.
c Anaemia (broad) is defined as a Hb level of < 13 g/dl in men or < 12 g/dl in women.
d Anaemia (strict) is defined as a Hb level of < 11 g/dl in men or < 10 g/dl in women, or a Hb level of ≥ 11 g/dl and < 13 g/dl
in men or ≥ 10 g/dl and < 12 g/dl in women accompanied by microcytosis (MCV of < 80 fl) or low ferritin (< 20 µg/l).
e IDA (broad) is defined as a Hb level of < 13 g/dl in men or < 12 g/dl in women accompanied by microcytosis (MCV of
< 80 fl) or low ferritin (< 20 µg/l).
f IDA (strict) is defined as a Hb level of < 13 g/dl in men or < 12 g/dl in women accompanied by low ferritin (< 20 µg/l).
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Anaemia, by the broad and strict definitions, was the most frequently reported clinical sign for proximal
cancer, reported in 80.2% and 62.5%, respectively, of proximal cancer patients. Anaemia was also reported
frequently in patients with distal cancer (44.2% for the broad definition). The sensitivities of IDA for proximal
cancer by the broad (50.0%) and strict (20.8%) definitions were lower than those of anaemia.
The NICE qualifying features that were more frequently reported by patients with distal cancer than by
those with proximal cancer were a CIBH (p = 0.002), rectal bleeding (p < 0.001) and rectal mass
(p = 0.008). By contrast, abdominal pain (p = 0.012) and anaemia/IDA (p < 0.001) were more frequently
reported by patients with proximal cancer than by patients with distal cancer (see Table 13).
Symptomatic presentation of proximal colon cancer and distal colorectal
cancer diagnoses by clinical features in isolation and in combination
A small proportion (9.3%; n = 16) of the 172 distal cancers diagnosed in patients with a CIBH were
diagnosed in those with a CIBH alone (Table 14), in comparison to a high proportion (59.9%; n = 103)
diagnosed among individuals who also reported rectal bleeding. Of the 52 proximal cancers diagnosed in
patients with a CIBH, only four (7.7%) were diagnosed in those with a CIBH alone and 11 (21.2%) in those
who also had rectal bleeding. However, when anaemia was also reported, 35 (67.3%) of these proximal
cancers were captured.
Abdominal pain and weight loss as single clinical features were not predictive of either distal or proximal
cancer (see Table 14). The majority of distal cancers in patients with abdominal pain (78.4%) and weight
loss (74.0%) were diagnosed in those who also had a CIBH. Furthermore, the majority of proximal cancers
in those with abdominal pain (n = 22) were in patients who also had a CIBH (66.7%) or anaemia (66.7%).
Similarly, the majority of proximal cancers in those with weight loss occurred in patients who had this
symptom in combination with a CIBH (66.7%) or anaemia (87.5%). No cancers were diagnosed in patients
with weight loss alone.
Anaemia was notable out of all the NICE qualifying features for indicating a high ratio of proximal to
distal cancers, which was in contrast to any other NICE guideline symptom (see Table 14). The ratios of
proximal to distal cancer increased as the definitions for anaemia/IDA were tightened. The highest ratio
was observed in patients with IDA by the strict definition (20 proximal cancers vs. 12 distal cancers). By
contrast, anaemia by the broadest definition was not as specific for proximal cancer (77 proximal cancers
vs. 106 distal cancers). Out of the 77 proximal cancers found in patients with anaemia (broad definition),
22 (28.6%) were found in patients with no other NICE qualifying features. Similarly, 8 out of 20 (40.0%)
proximal cancers in patients with IDA were diagnosed in those who had this sign alone. Relative yields of
distal cancers were higher in patients with anaemia/IDA (by any definition used) in combination with rectal
bleeding. Using the broad definition of anaemia, 59 distal cancers were diagnosed in patients who also
reported rectal bleeding, compared with 14 proximal cancers.
The NICE qualifying symptom associated with the highest proportionate number of patients diagnosed
with distal cancer versus proximal cancer, regardless of other presenting clinical features, was rectal
bleeding: when patients presented with this symptom, 89.5% of those diagnosed with cancer had distal
cancer (Table 15).
Rectal bleeding was examined in further detail as a symptom alone and in combination with other
symptoms (Table 16). Among patients presenting with rectal bleeding alone, 89.5% (n = 17) of those
diagnosed with cancer had a distal tumour. When rectal bleeding and a CIBH were reported together in
the absence of anaemia, 95.8% (n = 69) of patients diagnosed with cancer had a distal cancer. This
increased to 100.0% (n = 10) when the CIBH was reported as harder and/or less frequent defecation.
RESULTS
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Occurrence of any additional NICE 2015 guideline symptoms or signsa







































CIBH 3472 172 52 16 4 – – 103 11 40 22 37 16 67 35 8 5 7 0
Rectal bleeding 1660 154 20 19 2 103 11 – – 26 5 23 5 59 14 2 3 13 0
Abdominal pain 1367 51 33 1 0 40 22 26 5 – – 16 10 21 22 5 6 0 0
Weight loss 881 50 24 0 0 37 16 23 5 16 10 – – 31 21 4 3 0 0
Bloating/flatulence 131 6 3 0 0 4 3 3 0 2 0 1 1 2 2 1 0 0 0
Tiredness/weakness 114 7 4 0 0 6 4 3 1 1 2 6 1 5 4 2 1 0 0
Anal symptoms 56 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0
Nausea/vomiting 32 3 0 0 0 1 0 1 0 0 0 1 0 3 0 1 0 0 0
Back pain 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Upper GI symptoms 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Signs/indications
Anaemia
Anaemia (broad)b 1659 106 77 8 22 67 35 59 14 21 22 31 21 – – 5 7 3 0
Anaemia (strict)c 875 52 60 6 20 32 27 30 9 10 16 18 13 – – 3 5 1 0
IDA (broad)d 567 36 48 6 18 20 21 21 5 7 13 11 10 – – 1 5 1 0
IDA (strict)e 318 12 20 2 8 7 8 8 1 5 4 3 5 – – 0 0 1 0
Abdominal mass 140 10 8 0 0 8 5 2 3 5 6 4 3 5 7 – – 0 0









































































































































































Occurrence of any additional NICE 2015 guideline symptoms or signsa






































FOBt positive 76 6 2 0 0 3 0 1 0 2 1 2 0 5 2 0 0 0 0
Family history 69 3 2 0 0 3 2 3 0 2 2 1 0 0 1 0 0 0 0
History of polyps 14 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0
Other signsf 11 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Shading indicates NICE 2015 guideline76 signs/symptoms/indications.
a Three patients had both distal and proximal cancer diagnosed and each patient is included in both the distal and proximal cancer columns.
b Anaemia (broad) is defined as a Hb level of < 13 g/dl in men or < 12 g/dl in women.
c Anaemia (strict) is defined as a Hb level of < 11 g/dl in men or < 10 g/dl in women, or a Hb level of ≥ 11 g/dl and < 13 g/dl in men or ≥ 10 g/dl and < 12 g/dl in women accompanied by
microcytosis (MCV of < 80 fl) or low ferritin (< 20 µg/l).
d IDA (broad) is defined as a Hb level of < 13 g/dl in men or < 12 g/dl in women accompanied by microcytosis (MCV of < 80 fl) or low ferritin (< 20 µg/l).
e IDA (strict) is defined as a Hb level of < 13 g/dl in men or < 12 g/dl in women accompanied by low ferritin (< 20 µg/l).

















Patients with cancer, n Percentage of patients
with cancer who have
distal cancerDistal Proximal
Total 333 240 96 72
Symptoms
CIBH 222 172 52 77
Looser and/or more frequent 121 97 26 80
Harder and/or less frequent 40 28 12 70
Variable 17 12 5 71
Unspecified 44 35 9 80
Rectal bleeding 172 154 20 90
Abdominal pain 83 51 33 61
Weight loss 72 50 24 69
Bloating/flatulence 9 6 3 67
Tiredness/weakness 11 7 4 64
Anal symptoms 1 1 0 100
Nausea/vomiting 3 3 0 100
Back pain 0 0 0 –
Upper GI symptoms 0 0 0 –
Signs/indications
Anaemia
Anaemia (broad)b 181 106 77 59
Anaemia (strict)c 111 52 60 47
IDA (broad)d 83 36 48 43
IDA (strict)e 32 12 20 37
Abdominal mass 18 10 8 56
Rectal mass 15 15 0 100
FOBt positive 8 6 2 75
Family history 5 3 2 60
History of polyps 1 0 1 0
Other signsf 0 0 0 –
Shading indicates NICE 2015 guideline76 signs/symptoms/indications.
a Three patients had both distal and proximal cancer diagnosed and each patient is included in both the distal and
proximal cancer columns.
b Anaemia (broad) is defined as a Hb level of < 13 g/dl in men or < 12 g/dl in women.
c Anaemia (strict) is defined as a Hb level of < 11 g/dl in men or < 10 g/dl in women, or a Hb level of ≥ 11 g/dl and < 13 g/dl
in men or ≥ 10 g/dl and < 12 g/dl in women accompanied by microcytosis (MCV of < 80 fl) or low ferritin (< 20 µg/l).
d IDA (broad) is defined as a Hb level of < 13 g/dl in men or < 12 g/dl in women accompanied by microcytosis (MCV of
< 80 fl) or low ferritin (< 20 µg/l).
e IDA (strict) is defined as a Hb level of < 13 g/dl in men or < 12 g/dl in women accompanied by low ferritin (< 20 µg/l).
f Other signs include the presence of cancer antibodies, elevated C-reactive protein or liver problems.
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A more detailed examination of CIBH revealed generally lower proportions of distal cancer than when
presenting symptoms included rectal bleeding (Table 17). When patients presented with a CIBH alone,
83.3% (n = 15) of those diagnosed with cancer had distal cancer. Of patients with cancer who presented
with a CIBH and anaemia, between 57.9% and 71.7% had distal cancers, with proportionately more distal
cancers in those reporting a change to looser and/or more frequent stools and anaemia (n = 38) than in
those with a change to harder stools and/or less frequent defecation and anaemia (n = 11).
It has previously been reported that proportionately fewer proximal cancers are diagnosed in patients
without anaemia and/or an abdominal mass.31,33 Here, of the 187 patients diagnosed with cancer who
presented with anaemia or an abdominal mass, 59.4% (n = 111) had distal cancer (Table 18). In patients
diagnosed with cancer who had presented without anaemia or an abdominal mass, the proportions with
distal cancer varied by symptom combination. Overall, 88.4% of patients (n = 129) without anaemia or an





Patients with cancer, n Percentage of patients
with cancer who have
distal cancerDistal Proximal
Rectal bleeding 172 154 20 90
Rectal bleeding with anaemiab 72 59 14 82
Rectal bleeding without anaemiab 100 95 6 95
+ CIBH 72 69 4 96
Looser and/or more frequent 43 40 4 93
Harder and/or less frequent 10 10 0 100
Variable 2 2 0 100
Unspecified 17 17 0 100
+ Abdominal pain 16 15 2 94
+Weight loss 10 10 1 100
+ Abdominal mass 1 0 1 0
+ Rectal mass 10 10 0 100
+ FOBt positive 0 0 0 –
+ Any non-guideline symptom 7 7 0 100
Rectal bleeding with neither
anaemiab nor CIBH
28 26 2 93
+ Abdominal pain 2 2 0 100
+Weight loss 1 1 0 100
+ Abdominal mass 0 0 0 –
+ Rectal mass 5 5 0 100
+ FOBt positive 0 0 0 –
+ Any non-guideline symptom 2 2 0 100
Rectal bleeding alone 19 17 2 89
a Two patients had both distal and proximal cancer diagnosed and each patient is included in both the distal and proximal
cancer columns.
b Anaemia (broad) is defined as a Hb level of < 13 g/dl in men or < 12 g/dl in women.
RESULTS
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abdominal mass who had cancer had distal cancer; among these patients, a report of rectal bleeding
increased this proportion to 96.0% (n = 95). By contrast, in patients without anaemia or abdominal mass
who reported a CIBH but without rectal bleeding, only 71.1% (n = 32) of patients with cancer had
distal cancer.










with cancer who have
distal cancer
CIBH 222 172 52 77
CIBH with anaemiab 101 67 35 66
Looser and/or more frequent 53 38 16 72
Harder and/or less frequent 19 11 8 58
Variable 9 6 3 67
Unspecified 20 12 8 60
CIBH without anaemiab 121 105 17 87
Looser and/or more
frequent
68 59 10 87
Harder and/or less frequent 21 17 4 81
Variable 8 6 2 75
Unspecified 24 23 1 96
+ Rectal bleeding 72 69 4 96
+ Abdominal pain 36 26 11 72
+Weight loss 20 18 3 90
+ Abdominal mass 5 4 1 80
+ Rectal mass 6 6 0 100
+ FOBt positive 1 1 0 100
+ Any non-guideline symptom 10 8 2 80
CIBH with neither anaemiab nor
rectal bleeding
49 36 13 73
+ Abdominal pain 22 13 9 59
+Weight loss 11 9 2 82
+ Abdominal mass 4 4 0 100
+ Rectal mass 1 1 0 100
+ FOBt positive 1 1 0 100
+ Any non-guideline symptom 5 3 2 60
CIBH alone 18 15 3 83
a Two patients had both distal and proximal cancer diagnosed and each patient is included in both the distal and proximal
cancer columns.
b Anaemia (broad) is defined as a Hb level of < 13 g/dl in men or < 12 g/dl in women.
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Diagnostic yields of clinical features for proximal and distal colorectal cancers
The overall diagnostic yield for distal cancer was more than twice that for proximal cancer (5.1% vs. 2.0%)
and, as a corollary, fewer patients needed to be examined to diagnose one distal (20 patients, 95% CI
18 to 23 patients) than one proximal cancer (50 patients, 95% CI 41 to 61 patients) (Table 19). The
diagnostic yields were higher for distal cancer than for proximal cancer for all NICE qualifying symptoms.
The yields for proximal cancer were < 3% for all NICE qualifying symptoms. The highest diagnostic yield
for distal cancer was observed in patients with rectal bleeding; out of the 1660 patients who presented
with rectal bleeding, 154 (9.3%) were diagnosed with distal cancer, resulting in a low number who
needed to be examined to diagnose one cancer (11, 95% CI 10 to 13). By contrast, only 1.2% patients
(n = 20) with rectal bleeding were diagnosed with proximal cancer.




Patients with cancer, n Percentage of patients
with cancer who have
distal cancerDistal Proximal
Total 333 240 96 72
Anaemiab or abdominal mass 187 111 78 59
No anaemiab or abdominal mass 146 129 18 88
Rectal bleeding, no anaemia or abdominal mass
Total 99 95 5 96
Rectal bleeding alone 19 17 2 89
Rectal bleeding and CIBH 71 69 3 97
Rectal bleeding and either
weight loss or abdominal pain,
and no CIBH
2 2 0 100
Rectal bleeding and only other
symptoms or signs
7 7 0 100
CIBH, no anaemia, abdominal mass or rectal bleeding
Total 45 32 13 71
CIBH alone 18 15 3 83
Looser and/or more frequent 9 9 0 100
Harder and/or less frequent 5 3 2 60
Variable 3 3 0 100
Unspecified 1 0 1 0
CIBH and weight loss or
abdominal pain
24 15 9 62
CIBH and only other symptoms
or signs
3 2 1 67
No anaemia, abdominal mass, rectal bleeding or CIBH
Abdominal pain or weight loss 1 1 0 100
Only other symptoms or signs 1 1 0 100
a Three patients had both distal and proximal cancer diagnosed and each patient is included in both the distal and
proximal cancer columns.
b Anaemia (broad) is defined as a Hb level of < 13 g/dl in men or < 12 g/dl in women.
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Total 4741 (100) 240 5.1 20 (18 to 23) 96 2.0 50 (41 to 61)
Symptoms
CIBH 3472 (73.2) 172 5.0 21 (18 to 24) 52 1.5 67 (52 to 90)
Looser and/or
more frequent
1852 (39.1) 97 5.2 20 (16 to 24) 26 1.4 72 (49 to 109)
Harder and/or
less frequent
583 (12.3) 28 4.8 21 (15 to 32) 12 2.1 49 (29 to 94)
Variable 418 (8.8) 12 2.9 35 (21 to 68) 5 1.2 84 (37 to 257)
Unspecified 619 (13.1) 35 5.7 18 (13 to 26) 9 1.5 69 (37 to 150)
Rectal bleeding 1660 (35.0) 154 9.3 11 (10 to 13) 20 1.2 83 (54 to 136)
Abdominal pain 1367 (28.8) 51 3.7 27 (21 to 36) 33 2.4 42 (30 to 60)
Weight loss 881 (18.6) 50 5.7 18 (14 to 24) 24 2.7 37 (25 to 58)
Bloating/
flatulence
131 (2.8) 6 4.6 22 (11 to 59) 3 2.3 44 (16 to 211)
Tiredness/
weakness
114 (2.4) 7 6.1 17 (9 to 40) 4 3.5 29 (12 to 104)
Anal symptoms 56 (1.2) 1 1.8 56 (11 to 2213) 0 0 –
Nausea/vomiting 32 (0.7) 3 9.4 11 (4 to 51) 0 0 –
Back pain 7 (0.1) 0 0 – 0 0 –
Upper GI
symptoms





1659 (35.0) 106 6.4 16 (14 to 20) 77 4.6 22 (18 to 28)
Anaemia
(strict)c
875 (18.5) 52 5.9 17 (13 to 23) 60 6.9 15 (12 to 19)
IDA (broad)d 567 (12.0) 36 6.3 16 (12 to 23) 48 8.5 12 (10 to 16)
IDA (strict)e 318 (6.7) 12 3.8 27 (16 to 51) 20 6.3 16 (11 to 26)
Abdominal mass 140 (3.0) 10 7.1 14 (8 to 29) 8 5.7 18 (10 to 41)
Rectal mass 81 (1.7) 15 18.5 6 (4 to 10) 0 0 –
FOBt positive 76 (1.6) 6 7.9 13 (7 to 34) 2 2.6 38 (11 to 313)
Family history 69 (1.5) 3 4.3 23 (9 to 111) 2 2.9 35 (10 to 284)
continued
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Using NICE qualifying clinical signs, the highest diagnostic yield for proximal cancer was observed in
patients with IDA (by the broad definition), of whom 8.5% were diagnosed with proximal cancer.
The diagnostic yields in patients who presented with an abdominal mass were comparatively high for both
proximal (5.7%) and distal cancer (7.1%). None of the 81 patients with rectal mass were diagnosed with
proximal cancer, but this sign was highly predictive of distal cancer (diagnostic yield 18.5%).
In the 1660 patients with rectal bleeding for whom blood test data were available, diagnostic yields for
distal cancer were as high, at 34.5% among those with a rectal mass and 11.9% for a CIBH to looser and/or
more frequent stools (Table 20). By contrast, diagnostic yields for proximal cancer were approximately ≤ 1%,
except in patients with anaemia (2.8%) or an abdominal mass (5.9%), and there was a large degree of
uncertainty in the numbers needed to be examined to diagnose one proximal cancer. The diagnostic yield
for distal cancer was notably higher in non-anaemic patients who had rectal bleeding in combination with
rectal mass (34.5%); however, > 1 in 10 patients with rectal bleeding and anaemia were also diagnosed
with distal cancer (diagnostic yield 11.8%).
In patients with a CIBH, the highest diagnostic yields were once again observed for distal cancer (Table 21).
Yields of up to 21.4% were observed for distal cancer in patients with a CIBH in combination with rectal
mass, although only 15 out of 833 patients who presented with a CIBH alone were diagnosed with distal
cancer (diagnostic yield 1.8%). Yields for proximal cancer were generally ≤ 4% in patients with a CIBH.
Of the NICE qualifying features, the presence of anaemia and/or an abdominal mass was associated with the
highest diagnostic yield for proximal cancer, with 4.5% of these patients (n = 78) being diagnosed with
proximal cancer (Table 22). In patients without anaemia or an abdominal mass, no other NICE qualifying
features, either in isolation or in combination, exhibited diagnostic yields for proximal cancer of more than
approximately 1%, with the exception of a CIBH to harder stools and/or less frequent defecation (diagnostic
yield 2.2%). There was evidence to suggest that NICE qualifying features were more predictive of distal cancer
than of proximal cancer in patients without anaemia or an abdominal mass (overall diagnostic yield of 4.3%
vs. 0.6% for distal and proximal cancer, respectively). In particular, rectal bleeding, either alone or in
combination with other clinical features, was associated with diagnostic yields of up to 17.5% (range
1.7–17.5%) for distal cancer but < 0.8% for proximal cancer.
TABLE 19 Diagnostic yield of distal and proximal cancers by symptoms and signs/indications in 4741 patients with




























History of polyps 14 (0.3) 0 0 – 1 7.1 14 (3 to 554)
Other signsf 11 (0.2) 0 0 – 0 0 –
Shading indicates NICE 2015 guideline76 signs/symptoms/indications.
a Three patients had both distal and proximal cancer diagnosed and each patient is included in both the distal and
proximal cancer columns.
b Anaemia (broad) is defined as a Hb level of < 13 g/dl in men or < 12 g/dl in women.
c Anaemia (strict) is defined as a Hb level of < 11 g/dl in men or < 10 g/dl in women, or a Hb level of ≥ 11 g/dl and < 13 g/dl
in men or ≥ 10 g/dl and < 12 g/dl in women accompanied by microcytosis (MCV of < 80 fl) or low ferritin (< 20 µg/l).
d IDA (broad) is defined as a Hb level of < 13 g/dl in men or < 12 g/dl in women accompanied by microcytosis (MCV of
< 80 fl) or low ferritin (< 20 µg/l).
e IDA (strict) is defined as a Hb level of < 13 g/dl in men or < 12 g/dl in women accompanied by low ferritin (< 20 µg/l).
f Other signs include the presence of cancer antibodies, elevated C-reactive protein or liver problems.
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Rectal bleeding 1660 154 9.3 11 (10 to 13) 20 1.2 83 (54 to 136)
Rectal bleeding with
anaemiab
501 59 11.8 9 (7 to 12) 14 2.8 36 (22 to 66)
Rectal bleeding
without anaemiab
1159 95 8.2 13 (11 to 15) 6 0.5 194 (90 to 526)
+ CIBH 736 69 9.4 11 (9 to 14) 4 0.5 184 (73 to 675)
Looser and/or
more frequent
367 40 10.9 10 (7 to 13) 4 1.1 92 (37 to 336)
Harder and/or
less frequent
144 10 6.9 15 (9 to 30) 0 0 –
Variable 82 2 2.4 41 (12 to 337) 0 0 –
Unspecified 143 17 11.9 9 (6 to 15) 0 0 –
+ Abdominal pain 289 15 5.2 20 (12 to 35) 2 0.7 145 (41 to 1192)
+Weight loss 132 10 7.6 14 (8 to 28) 1 0.8 132 (25 to 5215)
+ Abdominal mass 17 0 0 – 1 5.9 17 (4 to 672)
+ Rectal mass 29 10 34.5 3 (2 to 6) 0 0 –
+ FOBt positive 6 0 0 – 0 0 –
+ Any non-
guideline symptom




423 26 6.1 17 (12 to 25) 2 0.5 212 (59 to 1745)
+ Abdominal pain 100 2 2.0 50 (15 to 412) 0 0 –
+Weight loss 37 1 2.7 37 (8 to 1462) 0 0 –
+ Abdominal mass 7 0 0 – 0 0 –
+ Rectal mass 15 5 33.3 3 (2 to 9) 0 0 –
+ FOBt positive 3 0 0 – 0 0 –
+ Any non-
guideline symptom
31 2 6.5 16 (5 to 127) 0 0 –
Rectal bleeding alone 260 17 6.5 16 (10 to 26) 2 0.8 130 (37 to 1072)
a Two patients had both distal and proximal cancer diagnosed and each patient is included in both the distal and proximal
cancer columns.
b Anaemia (broad) is defined as a Hb level of < 13 g/dl in men or < 12 g/dl in women.
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CIBH 3472 172 5.0 21 (18 to 24) 52 1.5 67 (52 to 90)
CIBH with anaemiab 989 67 6.8 15 (12 to 19) 35 3.5 29 (21 to 41)
Looser and/or
more frequent
509 38 7.5 14 (10 to 19) 16 3.1 32 (20 to 56)
Harder and/or less
frequent
201 11 5.5 19 (11 to 37) 8 4.0 26 (14 to 58)
Variable 105 6 5.7 18 (9 to 48) 3 2.9 35 (13 to 169)
Unspecified 174 12 6.9 15 (9 to 28) 8 4.6 22 (12 to 50)
CIBH without
anaemiab
2483 105 4.2 24 (20 to 29) 17 0.7 147 (92 to 251)
Looser and/or
more frequent
1343 59 4.4 23 (18 to 30) 10 0.7 135 (74 to 280)
Harder and/or
less frequent
382 17 4.5 23 (15 to 39) 4 1.0 96 (38 to 350)
Variable 313 6 1.9 53 (25 to 142) 2 0.6 157 (44 to 1291)
Unspecified 445 23 5.2 20 (14 to 31) 1 0.2 445 (81 to 17,578)
+ Rectal bleeding 736 69 9.4 11 (9 to 14) 4 0.5 184 (73 to 675)
+ Abdominal pain 784 26 3.3 31 (12 to 46) 11 1.4 72 (41 to 143)
+Weight loss 414 18 4.3 23 (15 to 39) 3 0.7 138 (48 to 669)
+ Abdominal mass 52 4 7.7 13 (6 to 47) 1 1.9 52 (10 to 2055)
+ Rectal mass 28 6 21.4 5 (3 to 13) 0 0 –
+ FOBt positive 24 1 4.2 24 (5 to 949) 0 0 –
+ Any non-
guideline symptom




1747 36 2.1 49 (36 to 70) 13 0.7 135 (79 to 253)
+ Abdominal pain 595 13 2.2 46 (27 to 86) 9 1.5 67 (36 to 145)
+Weight loss 319 9 2.8 36 (19 to 78) 2 0.6 160 (45 to 1316)
+ Abdominal mass 42 4 9.5 11 (5 to 38) 0 0 –
+ Rectal mass 14 1 7.1 14 (3 to 554) 0 0 –
+ FOBt positive 21 1 4.8 21 (5 to 830) 0 0 –
+ Any non-
guideline symptom
169 3 1.8 57 (20 to 273) 2 1.2 85 (24 to 697)
CIBH alone 833 15 1.8 56 (34 to 99) 3 0.4 278 (96 to 1346)
a Two patients had both distal and proximal cancer diagnosed and each patient is included in both the distal and proximal
cancer columns.
b Anaemia (broad) is defined as a Hb level of < 13 g/dl in men or < 12 g/dl in women.
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Number needed to be
examined to diagnose
one cancer (95% CI)
Total 4741 (100) 240 5.1 20 (18 to 23) 96 2.0 50 (41 to 61)
Anaemiab or abdominal mass 1731 (36.5) 111 6.4 16 (14 to 19) 78 4.5 23 (18 to 28)
No anaemiab or abdominal mass 3010 (63.5) 129 4.3 24 (20 to 28) 18 0.6 168 (106 to 282)
Rectal bleeding, no anaemia or abdominal mass
Total 1142 (24.1) 95 8.3 13 (10 to 15) 5 0.4 229 (99 to 703)
Rectal bleeding alone 260 (5.5) 17 6.5 16 (10 to 26) 2 0.8 130 (37 to 1072)
Rectal bleeding and CIBH 726 (15.3) 69 9.5 11 (9 to 14) 3 0.4 242 (84 to 1173)
Rectal bleeding and either weight loss or abdominal
pain, and no CIBH
116 (2.4) 2 1.7 58 (17 to 478) 0 0 –
Rectal bleeding and only other symptoms or signs 40 (0.8) 7 17.5 6 (4 to 14) 0 0 –
CIBH, no anaemia, abdominal mass or rectal bleeding
Total 1705 (36.0) 32 1.9 54 (38 to 78) 13 0.8 132 (77 to 246)
CIBH alone 833 (17.6) 15 1.8 56 (34 to 99) 3 0.4 278 (96 to 1346)
Looser and/or more frequent 477 (10.1) 9 1.9 53 (29 to 116) 0 0 –
Harder and/or less frequent 90 (1.9) 3 3.3 30 (11 to 145) 2 2.2 45 (13 to 371)
Variable 100 (2.1) 3 3.0 34 (12 to 161) 0 0 –
Unspecified 166 (3.5) 0 0 – 1 0.6 166 (31 to 6558)
CIBH and weight loss or abdominal pain 790 (16.7) 15 1.9 53 (33 to 94) 9 1.1 88 (47 to 192)
CIBH and only other symptoms or signs 82 (1.7) 2 2.4 41 (12 to 337) 1 1.2 82 (16 to 3240)
No anaemia, abdominal mass, rectal bleeding or CIBH
Abdominal pain or weight loss 138 (2.9) 1 0.7 138 (26 to 5452) 0 0 –
Only other symptoms or signs 25 (0.5) 1 4.0 25 (5 to 988) 0 0 –
a Three patients had both distal and proximal cancer diagnosed and each patient is included in both the distal and proximal cancer columns.




































































































































































We examined the proportions of patients diagnosed with proximal and distal cancers by different
definitions of anaemia (anaemia broad, anaemia strict and IDA broad) (Table 23). Of the 95 patients with
cancer who presented with IDA and/or an abdominal mass, 47.4% (n = 45) were diagnosed with distal
cancer. Similar observations were made for patients with strict-definition anaemia and/or an abdominal
mass (n = 59; 48.8% distal cancer). There was some evidence to suggest that a slightly greater proportion
of cancers diagnosed in patients with broad definition anaemia and/or an abdominal mass were distal
(n = 111, 59.4%). Similar proportions of cancers diagnosed were distal in patients with a symptom profile
including rectal bleeding irrespective of the anaemia definition used (see Table 23).
Comparing the diagnostic yields and numbers needed to be examined in patients with anaemia or an
abdominal mass, with anaemia status defined by the strict definition (Table 24) and IDA by the broad
definition (Table 25), diagnostic yields for proximal cancer were similar (6.4% and 7.4%, respectively);
both of these estimates are higher than the 4.5% yield when the broad definition of anaemia is used
(see Table 22). The diagnostic yields for proximal cancer in patients without anaemia or an abdominal mass
by any definition were similar (range 0.6–1.1%). The number needed to be examined to diagnose one
proximal cancer in patients without IDA or an abdominal mass was 91 (95% CI 68 to 124; see Table 25),
compared with 114 (95% CI 82 to 166; see Table 24) for the strict definition of anaemia and 168 (95% CI
106 to 282; see Table 22) for the broad definition of anaemia.
We also examined the diagnostic yields and numbers needed to be examined for distal and proximal
cancers in patients with anaemia (all definitions) separate from an abdominal mass (Table 26). For distal
cancers, the highest diagnostic yields were observed in patients with anaemia with/without additional
symptoms (range 3.8–6.4%). Anaemia by the broadest definition was most predictive of distal cancer in this
group of patients, whereas IDA strict definition was least predictive. The diagnostic yield for proximal cancer
for all patients with anaemia, by any definition and regardless of whether or not they had additional
symptoms, ranged from 4.6% to 8.5%. For patients with anaemia, IDA by the broadest definition and IDA
by the strictest definition were the most and least predictive of proximal cancer, respectively.
Analyses in patients without blood test data
To compare the results in the patients with blood test data with the rest of the SOCCER study, proximal
and distal cancer diagnoses by clinical feature were examined in the 2639 patients in whom no blood
test data were available (Table 27). In this subset, anaemia was simply defined by a question (yes/no) on
the SIGGAR referral form and was not confirmed by laboratory data. The proportion of cancer diagnoses
that were distal was very similar in the cohort of patients in whom non-laboratory-confirmed anaemia or
an abdominal mass was the reason for referral (see Table 27) and in the cohort with laboratory-confirmed
anaemia status or an abdominal mass (58.1% vs. 59.4%) (see Table 18). Similarly, in patients without
anaemia or an abdominal mass, there was little difference in the proportion of cancer diagnoses that were
distal in patients with and without blood test data (88.4% vs. 93.7%, respectively).
Among the 2639 patients referred without blood test data, more were diagnosed with distal cancer
(n = 189, 7.2%) than with proximal cancer (n = 31, 1.2%) (Table 28). The diagnostic yields for distal and
proximal cancer in patients presenting with anaemia or an abdominal mass in the cohort without blood
test data were high (8.6% and 6.2%, respectively) and were similar to the yields in patients with blood
test data (see Table 22) (6.4% and 4.5%, respectively). The diagnostic yields for proximal cancer in the
patient cohorts with and without blood test data were also very similar for patients who presented without
anaemia or an abdominal mass (both 0.6%). By contrast, there was some evidence to suggest that the
diagnostic yield for distal cancer in patients presenting without anaemia or an abdominal mass was slightly
higher in the cohort without blood test data than in the cohort with blood test data (7.0% vs. 4.3%).
RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
40
TABLE 23 Subsite of CRCs by grouped symptoms and signs using different definitions of anaemia in 4741 patients with blood test data
Symptom/sign combinations
Anaemia (broad)a Anaemia (strict)b IDA (broad)c
Total,d n Distal, n Proximal, n
% with
distal
cancer Total,d n Distal, n Proximal, n
% with
distal




Total 333 240 96 72 333 240 96 72 333 240 96 72
Anaemia or abdominal mass 187 111 78 59 121 59 63 49 95 45 51 47
No anaemia or abdominal mass 146 129 18 88 212 181 33 85 238 195 45 82
Rectal bleeding, no anaemia or abdominal mass
Total 99 95 5 96 132 123 10 93 145 132 14 91
Rectal bleeding alone 19 17 2 89 28 25 3 89 31 27 4 87
Rectal bleeding and CIBH 71 69 3 97 90 85 6 94 98 91 8 93
Rectal bleeding and either
weight loss or abdominal
pain, and no CIBH
2 2 0 100 6 5 1 83 8 6 2 75
Rectal bleeding and only
other symptoms or signs
7 7 0 100 8 8 0 100 8 8 0 100
CIBH, no anaemia, abdominal mass or rectal bleeding
Total 45 32 13 71 66 50 17 76 74 54 21 73
CIBH alone 18 15 3 83 28 25 3 89 32 28 4 87
Looser and/or more
frequent
9 9 0 100 17 17 0 100 18 18 0 100
Harder and/or less
frequent
5 3 2 60 5 3 2 60 5 3 2 60
Variable 3 3 0 100 5 5 0 100 6 6 0 100





































































































































































TABLE 23 Subsite of CRCs by grouped symptoms and signs using different definitions of anaemia in 4741 patients with blood test data (continued )
Symptom/sign combinations
Anaemia (broad)a Anaemia (strict)b IDA (broad)c
Total,d n Distal, n Proximal, n
% with
distal
cancer Total,d n Distal, n Proximal, n
% with
distal




CIBH and weight loss or
abdominal pain
24 15 9 62 34 22 13 65 38 23 16 61
CIBH and only other
symptoms or signs
3 2 1 67 4 3 1 75 4 3 1 75
No anaemia, abdominal mass, rectal bleeding or CIBH
Abdominal pain or
weight loss
1 1 0 100 9 5 4 56 12 6 6 50
Only other symptoms
or signs
1 1 0 100 5 3 2 60 7 3 4 43
a Anaemia (broad) is defined as a Hb level of < 13 g/dl in men or < 12 g/dl in women.
b Anaemia (strict) is defined as a Hb level of < 11 g/dl in men or < 10 g/dl in women, or a Hb level of ≥ 11 g/dl and < 13 g/dl in men or ≥ 10 g/dl and < 12 g/dl in women accompanied by
microcytosis (MCV of < 80 fl) or low ferritin (< 20 µg/l).
c IDA (broad) is defined as a Hb level of < 13 g/dl in men or < 12 g/dl in women accompanied by microcytosis (MCV of < 80 fl) or low ferritin (< 20 µg/l).
























Number needed to be
examined to diagnose





Number needed to be
examined to diagnose
one cancer (95% CI)
Total 4741 (100) 240 5.1 20 (18 to 23) 96 2.0 50 (41 to 61)
Anaemiab or abdominal mass 981 (20.7) 59 6.0 17 (14 to 22) 63 6.4 16 (13 to 21)
No anaemiab or abdominal mass 3760 (79.3) 181 4.8 21 (19 to 25) 33 0.9 114 (82 to 166)
Rectal bleeding, no anaemia or abdominal mass
Total 1405 (29.6) 123 8.8 12 (10 to 14) 10 0.7 141 (77 to 293)
Rectal bleeding alone 337 (7.1) 25 7.4 14 (10 to 21) 3 0.9 113 (39 to 544)
Rectal bleeding and CIBH 887 (18.7) 85 9.6 11 (9 to 13) 6 0.7 148 (69 to 403)
Rectal bleeding and either weight loss or
abdominal pain, and no CIBH
134 (2.8) 5 3.7 27 (12 to 82) 1 0.7 134 (25 to 5294)
Rectal bleeding and only other symptoms or signs 47 (1.0) 8 17.0 6 (4 to 14) 0 0 –
CIBH, no anaemia, abdominal mass or rectal bleeding
Total 2083 (43.9) 50 2.4 42 (32 to 56) 17 0.8 123 (77 to 211)
CIBH alone 994 (21.0) 25 2.5 40 (28 to 62) 3 0.3 332 (114 to 1606)
Looser and/or more frequent 571 (12.0) 17 3.0 34 (22 to 58) 0 0 –
Harder and/or less frequent 115 (2.4) 3 2.3 39 (14 to 185) 2 1.7 58 (17 to 474)
Variable 120 (2.5) 5 4.2 24 (11 to 74) 0 0 –
Unspecified 188 (4.0) 0 0 – 1 0.5 188 (35 to 7427)
CIBH and weight loss or abdominal pain 988 (20.8) 22 2.2 45 (30 to 72) 13 1.3 76 (45 to 143)
CIBH and only other symptoms or signs 101 (2.1) 3 3.0 34 (12 to 163) 1 1.0 101 (19 to 3990)
No anaemia, abdominal mass, rectal bleeding or CIBH
Abdominal pain or weight loss 182 (3.8) 5 2.7 37 (16 to 112) 4 2.2 46 (19 to 167)
Only other symptoms or signs 90 (1.9) 3 3.3 30 (11 to 145) 2 2.2 45 (13 to 371)
a Three patients had both distal and proximal cancer diagnosed and each patient is included in both the distal and proximal cancer columns.
b Anaemia (strict) is defined as a Hb level of < 11 g/dl in men or < 10 g/dl in women, or a Hb level of ≥ 11 g/dl and < 13 g/dl in men or ≥ 10 g/dl and < 12 g/dl in women accompanied by
















































































































































































be examined to diagnose





Number needed to be
examined to diagnose
one cancer (95% CI)
Total 4741 (100) 240 5.1 20 (18 to 23) 96 2.0 50 (41 to 61)
IDAb or abdominal mass 685 (14.4) 45 6.6 16 (12 to 21) 51 7.4 14 (11 to 18)
No IDAb or abdominal mass 4056 (85.6) 195 4.8 21 (19 to 24) 45 1.1 91 (68 to 124)
Rectal bleeding, no anaemia or abdominal mass
Total 1501 (31.7) 132 8.8 12 (10 to 14) 14 0.9 108 (65 to 196)
Rectal bleeding alone 369 (7.8) 27 7.3 14 (10 to 21) 4 1.1 93 (37 to 338)
Rectal bleeding and CIBH 938 (19.8) 91 9.7 11 (9 to 13) 8 0.9 118 (60 to 272)
Rectal bleeding and either weight loss or abdominal
pain, and no CIBH
144 (3.0) 6 4.2 24 (12 to 65) 2 1.4 72 (21 to 593)
Rectal bleeding and only other symptoms or signs 50 (1.1) 8 16.0 7 (4 to 14) 0 0 –
CIBH, no anaemia, abdominal mass or rectal bleeding
Total 2215 (46.7) 54 2.4 42 (32 to 55) 21 0.9 106 (70 to 171)
CIBH alone 1058 (22.3) 28 2.6 38 (27 to 57) 4 0.4 265 (104 to 970)
Looser and/or more frequent 608 (12.8) 18 3.0 34 (22 to 57) 0 0 –
Harder and/or less frequent 119 (2.5) 3 2.5 40 (14 to 192) 2 1.7 60 (17 to 490)
Variable 131 (2.8) 6 4.6 22 (11 to 59) 0 0 –
Unspecified 200 (4.2) 1 0.5 200 (37 to 7901) 2 1.0 100 (29 to 825)
CIBH and weight loss or abdominal pain 1051 (22.2) 23 2.2 46 (31 to 72) 16 1.5 66 (41 to 115)
CIBH and only other symptoms or signs 106 (2.2) 3 2.8 36 (13 to 171) 1 0.9 106 (20 to 4188)
No anaemia, abdominal mass, rectal bleeding or CIBH
Abdominal pain or weight loss 210 (4.4) 6 2.9 35 (17 to 95) 6 2.9 35 (17 to 95)
Only other symptoms or signs 130 (2.7) 3 2.3 44 (16 to 210) 4 3.1 33 (14 to 119)
a Three patients had both distal and proximal cancer diagnosed and each patient is included in both the distal and proximal cancer columns.




























































Total 4741 (100) 333 100 7.0 15 (13 to 16) 240 100 5.1 20 (18 to 23) 96 100 2.0 50 (41 to 61)
Anaemia and/or other symptoms
Anaemia (broad)b 1659 (35.0) 181 54 10.9 10 (8 to 11) 106 44 6.4 16 (14 to 20) 77 80 4.6 22 (18 to 28)
Anaemia (strict)c 875 (18.5) 111 33 12.7 8 (7 to 10) 52 22 5.9 17 (13 to 23) 60 63 6.9 15 (12 to 19)
IDA (broad)d 567 (12.0) 83 25 14.6 7 (6 to 9) 36 15 6.3 16 (12 to 23) 48 50 8.5 12 (10 to 16)
IDA (strict)e 318 (6.7) 32 10 10.1 10 (8 to 15) 12 5 3.8 27 (16 to 51) 20 21 6.3 16 (11 to 26)
Anaemia and no other NICE symptoms
Anaemia (broad)b 307 (6.5) 30 9 9.8 11 (8 to 15) 8 3 2.6 39 (20 to 89) 22 23 7.2 14 (10 to 23)
Anaemia (strict)c 243 (5.1) 26 8 10.7 10 (7 to 15) 6 3 2.5 41 (19 to 110) 20 21 8.2 13 (9 to 20)
IDA (broad)d 206 (4.3) 24 7 11.7 9 (6 to 14) 6 3 2.9 35 (17 to 93) 18 19 8.7 12 (8 to 20)
IDA (strict)e 135 (2.8) 10 3 7.4 14 (8 to 28) 2 1 1.5 68 (20 to 556) 8 8 5.9 17 (9 to 39)
Anaemia and no other reported symptoms
Anaemia (broad)b 282 (5.9) 26 8 9.2 11 (8 to 17) 6 3 2.1 47 (22 to 128) 20 21 7.1 15 (10 to 23)
Anaemia (strict)c 230 (4.9) 23 7 10.0 10 (7 to 16) 5 2 2.2 46 (21 to 141) 18 19 7.8 13 (9 to 22)
IDA (broad)d 193 (4.1) 21 6 10.9 10 (7 to 15) 5 2 2.6 39 (17 to 119) 16 17 8.3 13 (8 to 21)
IDA (strict)e 125 (2.6) 8 2 6.4 16 (9 to 36) 2 1 1.6 63 (18 to 515) 6 6 4.8 21 (10 to 57)
a Three patients had both distal and proximal cancer diagnosed and each patient is included in both the distal and proximal cancer columns.
b Anaemia (broad) is defined as a Hb level of < 13 g/dl in men or < 12 g/dl in women.
c Anaemia (strict) is defined as a Hb level of < 11 g/dl in men or < 10 g/dl in women, or a Hb level of ≥ 11 g/dl and < 13 g/dl in men or ≥ 10 g/dl and < 12 g/dl in women accompanied by
microcytosis (MCV of < 80 fl) or low ferritin (< 20 µg/l).
d IDA (broad) is defined as a Hb level of < 13 g/dl in men or < 12 g/dl in women accompanied by microcytosis (MCV of < 80 fl) or low ferritin (< 20 µg/l).




































































































































































Analyses in the full SOCCER patient cohort
In the full SOCCER cohort, 77.9% (n = 429) of patients diagnosed with cancer were diagnosed with distal
cancer (Table 29). Among those diagnosed with cancer, 59.1% (n = 136) of all patients who presented
with anaemia or an abdominal mass had distal cancer, which was similar to the percentage in the cohort
with blood test data (59.4%) (see Table 18). Of the 321 cancer patients in the full cohort who did not
present with anaemia or an abdominal mass, 293 had distal cancer (91.3%), which was similar to the
proportion with distal cancer observed in the cohort of patients with blood test data (88.4%). Furthermore,
the proportions of patients diagnosed with distal cancer among those who presented without anaemia
or an abdominal mass and with rectal bleeding were similar in the full cohort and the reduced cohort
(94.4% and 96.0%, respectively). Similar to the findings in the cohort with blood test data, there was more
variation in the proportions of patients without anaemia or an abdominal mass with distal cancer who
presented with symptom profiles including a CIBH (range 71.4–100.0%).




Patients with cancer, n Percentage of patients
with cancer who have
distal cancerDistal Proximal
Total 218 189 31 87
Anaemiab or abdominal mass 43 25 18 58
No anaemiab or abdominal mass 175 164 13 94
Rectal bleeding, no anaemia or abdominal mass
Total 135 126 9 93
Rectal bleeding alone 28 26 2 93
Rectal bleeding and CIBH 94 87 7 93
Rectal bleeding and either
weight loss or abdominal pain,
no CIBH
6 6 0 100
Rectal bleeding and only other
symptoms or signs
7 7 0 100
CIBH, no anaemia, abdominal mass or rectal bleeding
Total 38 36 4 95
CIBH alone 17 16 2 94
Looser and/or more frequent 6 6 0 100
Harder and/or less frequent 2 2 0 100
Variable 6 5 1 83
Unspecified 3 3 1 100
CIBH and weight loss or
abdominal pain
20 19 1 95
CIBH and only other symptoms
or signs
1 1 1 100
No anaemia, abdominal mass, rectal bleeding or CIBH
Abdominal pain or weight loss 1 1 0 100
Only other symptoms or signs 1 1 0 100
a Two patients had both distal and proximal cancer diagnosed and each patient is included in both the distal and proximal
cancer columns.
b A patient was defined as having anaemia if anaemia was mentioned as a reason for referral.
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Number needed to be
examined to diagnose
one cancer (95% CI)
Total 2639 (100) 189 7.2 14 (13 to 17) 31 1.2 86 (61 to 126)
Anaemiab or abdominal mass 290 (11.0) 25 8.6 12 (9 to 18) 18 6.2 17 (11 to 27)
No anaemiab or abdominal mass 2349 (89.0) 164 7.0 15 (13 to 17) 13 0.6 181 (106 to 339)
Rectal bleeding, no anaemia or abdominal mass
Total 1054 (39.9) 126 12.0 9 (8 to 10) 9 0.9 118 (62 to 256)
Rectal bleeding alone 312 (11.8) 26 8.3 12 (9 to 19) 2 0.6 156 (44 to 1287)
Rectal bleeding and CIBH 619 (23.5) 87 14.1 8 (6 to 9) 7 1.1 89 (44 to 220)
Rectal bleeding and either weight loss or abdominal
pain, and no CIBH
86 (3.3) 6 7.0 15 (7 to 39) 0 0 –
Rectal bleeding and only other symptoms or signs 37 (1.4) 7 18.9 6 (3 to 13) 0 0 –
CIBH, no anaemia, abdominal mass or rectal bleeding
Total 1161 (44.0) 36 3.1 33 (24 to 46) 4 0.3 291 (114 to 1065)
CIBH alone 631 (23.9) 16 2.5 40 (25 to 69) 2 0.3 316 (88 to 2604)
Looser and/or more frequent 359 (13.6) 6 1.7 60 (28 to 163) 0 0 –
Harder and/or less frequent 84 (3.2) 2 2.4 42 (12 to 346) 0 0 –
Variable 66 (2.5) 5 7.6 14 (6 to 40) 1 1.5 66 (13 to 2608)
Unspecified 122 (4.6) 3 2.5 41 (15 to 197) 1 0.8 122 (23 to 4820)
CIBH and weight loss or abdominal pain 463 (17.5) 19 4.1 25 (16 to 41) 1 0.2 463 (84 to 18,289)
CIBH and only other symptoms or signs 67 (2.5) 1 1.5 67 (13 to 2647) 1 1.5 67 (13 to 2647)
No anaemia, abdominal mass, rectal bleeding or CIBH
Abdominal pain or weight loss 103 (3.9) 1 1.0 103 (19 to 4069) 0 0 –
Only other symptoms or signs 31 (1.2) 1 3.2 31 (6 to 1225) 0 0 –
a Two patients had both distal and proximal cancer diagnosed and each patient is included in both the distal and proximal cancer columns.




































































































































































In the full cohort, 27.4% (n = 2021) of patients were referred with anaemia or an abdominal mass (Table 30);
the diagnostic yields for proximal and distal cancer were similar (4.8% and 6.7%, respectively) and were
similar to the yields for proximal and distal cancer obtained in the patient cohort with blood test data (4.5%
and 6.4%, respectively) (see Table 22).
The diagnostic yield for proximal cancer was lower in the 72.6% (n = 5359) of patients referred without
anaemia or an abdominal mass in the full cohort and was similar to that obtained in the cohort with blood




Patients with cancer, n Percentage of patients
with cancer who have
distal cancerDistal Proximal
Total 551 429 127 78
Anaemiab or abdominal mass 230 136 96 59
Anaemia,b no abdominal mass 191 117 76 61
Abdominal mass, no anaemiab 21 11 10 52
Anaemiab and abdominal mass 18 8 10 44
No anaemiab or abdominal mass
Total 321 293 31 91
Rectal bleeding, no anaemia or abdominal mass
Total 234 221 14 94
Rectal bleeding alone 47 43 4 91
Rectal bleeding and CIBH 165 156 10 95
Rectal bleeding and either
weight loss or abdominal pain,
no CIBH
8 8 0 100
Rectal bleeding and only other
symptoms or signs
14 14 0 100
CIBH, no anaemia, abdominal mass or rectal bleeding
Total 83 68 17 82
CIBH alone 35 31 5 89
Looser and/or more frequent 15 15 0 100
Harder and/or less frequent 7 5 2 71
Variable 9 8 1 89
Unspecified 4 3 2 75
CIBH and weight loss or
abdominal pain
44 34 10 77
CIBH and only other symptoms
or signs
4 3 2 75
No anaemia, abdominal mass, rectal bleeding or CIBH
Abdominal pain or weight loss 2 2 0 100
Only other symptoms or signs 2 2 0 100
a Five patients had both distal and proximal cancer diagnosed and each patient is included in both the distal and proximal
cancer columns.
b In patients with blood test data, anaemia was determined only by blood test results and was defined here as a Hb level
of < 13 g/dl in men or < 12 g/dl in women. In patients without blood test data, anaemia was determined from
indications at referral and a patient was defined as having anaemia if anaemia was mentioned as a reason for referral.
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Number needed to be
examined to diagnose





Number needed to be
examined to diagnose
one cancer (95% CI)
Total 7380 (100) 429 5.8 18 (16 to 19) 127 1.7 59 (49 to 70)
Anaemiab or abdominal mass 2021 (27.4) 136 6.7 15 (13 to 18) 96 4.8 22 (18 to 26)
Anaemia,b no abdominal mass 1805 (24.5) 117 6.5 16 (13 to 19) 76 4.2 24 (20 to 31)
Abdominal mass, no anaemiab 133 (1.8) 11 8.3 13 (7 to 24) 10 7.5 14 (8 to 28)
Anaemiab and abdominal mass 83 (1.1) 8 9.6 11 (6 to 24) 10 12.0 9 (5 to 17)
No anaemiab or abdominal mass 5359 (72.6) 293 5.5 19 (17 to 21) 31 0.6 173 (122 to 255)
Rectal bleeding, no anaemia or abdominal mass
Total 2196 (29.8) 221 10.1 10 (9 to 12) 14 0.6 157 (94 to 287)
Rectal bleeding alone 572 (7.8) 43 7.5 14 (11 to 19) 4 0.7 143 (57 to 524)
Rectal bleeding and CIBH 1345 (18.2) 156 11.6 9 (8 to 11) 10 0.7 135 (74 to 281)
Rectal bleeding and either weight loss or abdominal
pain, and no CIBH
202 (2.7) 8 4.0 26 (14 to 58) 0 0 –
















































































































































































Number needed to be
examined to diagnose





Number needed to be
examined to diagnose
one cancer (95% CI)
CIBH, no anaemia, abdominal mass or rectal bleeding
Total 2866 (38.8) 68 2.4 43 (34 to 55) 17 0.6 169 (106 to 290)
CIBH alone 1464 (19.8) 31 2.1 48 (34 to 70) 5 0.3 293 (126 to 902)
Looser and/or more frequent 836 (11.3) 15 1.8 56 (34 to 100) 0 0 –
Harder and/or less frequent 174 (2.4) 5 2.9 35 (16 to 107) 2 1.1 87 (25 to 717)
Variable 166 (2.2) 8 4.8 21 (11 to 48) 1 0.6 166 (31 to 6558)
Unspecified 288 (3.9) 3 1.0 96 (34 to 465) 2 0.7 144 (41 to 1188)
CIBH and weight loss or abdominal pain 1253 (17.0) 34 2.7 37 (27 to 54) 10 0.8 126 (69 to 261)
CIBH and only other symptoms or signs 149 (2.0) 3 2.0 50 (18 to 240) 2 1.3 75 (21 to 614)
No anaemia, abdominal mass, rectal bleeding or CIBH
Abdominal pain or weight loss 241 (3.3) 2 0.8 121 (34 to 994) 0 0 –
Only other symptoms or signs 56 (0.8) 2 3.6 28 (9 to 230) 0 0 –
a Five patients had both distal and proximal cancer diagnosed and each patient is included in both the distal and proximal cancer columns.
b In patients with blood test data, anaemia was determined only by blood test results and was defined here as a Hb level of < 13 g/dl in men or < 12 g/dl in women. In patients without













test data (both 0.6%). The diagnostic yields for distal cancer for the 29.8% (n = 2196) of patients referred
with a symptom profile including rectal bleeding were high (diagnostic yield range 4.0–18.2%) in the
full cohort and were similar to the yields obtained in the subgroup with blood test data (diagnostic yield
range 1.7–17.5%). This was also reflected in the low numbers needed to examine for distal cancer.
Only 10 patients (95% CI 9 to 12 patients) with rectal bleeding would need to be examined to diagnose one
distal cancer in the full cohort; by contrast, 157 patients (95% CI 94 to 287 patients) with rectal bleeding
would need to be examined to diagnose one proximal cancer. Notably, none of the 2.7% (n = 202) of
patients referred with rectal bleeding and weight loss/abdominal pain in the absence of a CIBH had proximal
cancer (see Table 30).
The diagnostic yields for distal cancer in patients referred with a symptom profile including a CIBH were
generally lower than those for rectal bleeding in the full cohort (see Table 30). Among the 2866 patients
(38.8% of the full cohort) referred with a CIBH without rectal bleeding, distal cancer was diagnosed in
2.4% (n = 68). This yield was very similar to that observed in the cohort with blood test data (1.9%).
Diagnostic yields for distal cancer were similar for all CIBH subtypes (range 1.0–4.8%). CIBH was less
specific for proximal cancer than for distal cancer, reflected in the high numbers needed to examine (≥ 75),
and nearly all of the diagnostic yields were lower than 1% (range 0–1.3%). This was similar to the
observations in the cohort with blood test data. In the small number of patients (n = 297, 4.0%) in the full
cohort referred without anaemia, an abdominal mass, rectal bleeding or a CIBH, no proximal cancers were
diagnosed, which was also the case in the cohort with blood test data.
Patient profiles of proximal cancers diagnosed in those presenting with rectal bleeding
in the absence of anaemia or an abdominal mass
A total of 14 (45.2%) out of the 31 proximal cancers in patients without anaemia or an abdominal mass
were diagnosed in those with rectal bleeding (Table 31). Five of these patients had pathology or a clinical
finding in the distal colorectum that would probably have warranted a follow-on WCI after an initial FS
examination, of whom four were female and four were aged ≥ 69 years. Three of these five patients had
cancer located in the caecum and the majority (n = 3) presented with a CIBH to looser stools and/or more
frequent defecation in addition to rectal bleeding.
The majority (57.1%, n = 8) of the 14 patients with proximal cancer who presented with rectal bleeding
without anaemia or an abdominal mass did not have pathology or a clinical finding in the distal colorectum
that would have warranted follow-up by WCI. Three-quarters (n = 6) of these patients were male and all
were aged ≥ 63 years. Four of the proximal tumours in this group of patients were located in the caecum
and three-quarters (n = 6) of these patients had a CIBH to looser stools and/or more frequent defecation in
addition to rectal bleeding; only two patients in this group presented with rectal bleeding alone.
Proximal and distal cancer diagnostic yields in men and women aged < 70 years
or ≥ 70 years by symptoms/clinical signs
We looked at the influence of age and sex on the diagnostic yields for distal and proximal cancer by
symptoms that met criteria for FS (rectal bleeding or a CIBH to looser stools and/or more frequent defecation
only in the absence of anaemia/an abdominal mass) compared with symptoms that did not (Table 32).
Symptoms that met the criteria for FS were almost twice as predictive of distal cancer in men aged ≥ 70 years
as in men aged < 70 years (15.8% vs. 8.1%); similarly, the distal cancer diagnostic yield in women aged
≥ 70 years with these symptoms was approximately three times that for women aged < 70 years (8.3% vs.
3.1%). Distal cancer diagnostic yields in men and women with symptoms that did not meet the criteria for
FS were generally lower. Numbers needed to be examined to diagnose one distal cancer were quite low for
men irrespective of age group or whether or not their presenting symptoms met FS criteria (range 7–18).
In women, the numbers needed to be examined to diagnose one distal cancer were generally higher than
those for men and were higher in those aged < 70 years (32 and 46 for those meeting FS and not meeting
FS criteria, respectively) than in those aged ≥ 70 years (12 and 26 for those meeting and not meeting FS
criteria, respectively).
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Proximal cancer diagnostic yields were higher in men whose symptoms did not meet FS criteria than in
those whose did, irrespective of age (1.9% vs. 0.3% for those aged < 70 years and 3.6% vs. 1.0% for
those aged ≥ 70 years); this pattern was also observed in women. Importantly, in those presenting with
symptoms that met criteria for FS, diagnostic yields for proximal cancer were ≤ 1% (range 0.3–1.0%),
irrespective of age. The highest diagnostic yield for proximal cancer in patients with symptoms meeting FS
criteria was in men aged ≥ 70 years (1%). The number needed to be examined in order to diagnose one
proximal cancer in patients with symptoms meeting FS criteria was > 100 (range 104–385), irrespective of
age group and sex.
Flexible sigmoidoscopy examinations
A subset of patients received a FS examination at baseline, which presented an opportunity to assess the
CRC miss rate in this cohort (Table 33). Out of the total 7380 patients in the cohort, 20.1% (n = 1483) were
examined by FS at the time of referral. Men were as likely as women to be examined by FS (p = 0.67) and
there were no differences in the age profiles between those examined by FS and those not examined by FS








size (mm) Symptoms/signs/indications Distal findings
Distal findings that would necessitate referral for WCI
1 Male 80 CM Unknown RB, CIBH (looser/increase), AP FS finding: suspected cancer in
RM
2 Female 59 AC 45 RB, CIBH (looser/increase) 20-mm tubulovillous adenoma
in SC
3 Female 69 CM 50 RB Transported blood observed
distally; multiple sessile polyps
in RM (< 4mm)
4 Female 77 CM Unknown RB FS finding: ≥ 3 lesions




No reason for WCI
6 Male 63 SF 35 RB 8-mm tubulovillous adenoma in
RM
7 Male 69 TC 35 RB, CIBH (looser/increase) Multiple diverticula
8 Male 71 TC 25 RB, CIBH (looser/increase) Three hyperplastic polyps in SC
(all ≤ 7 mm), multiple diverticula
9 Male 78 CM 40 RB FS finding: complete and normal
10 Male 79 AC 30 RB, CIBH (looser/increase) 5-mm tubular adenoma in SC,
proctitis in RM
11 Male 81 CM 30 RB, CIBH (looser/increase) No abnormality reported
12 Female 65 CM 70 RB, CIBH (looser/increase) Multiple diverticula
13 Female 83 CM 70 RB, CIBH (looser/increase) No abnormality reported
No information on findings known
14 Female 68 CM Unknown RB, CIBH (looser/increase) No information
AC, ascending colon; AP, abdominal pain; CM, caecum; HF, hepatic flexure; RB, rectal bleeding; RM, rectum; SC, sigmoid
colon; SF, splenic flexure; TC, transverse colon; WL, weight loss.
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(p = 0.056). By contrast, the route and urgency of referral differed, with proportionately more patients who
underwent FS being referred to a colorectal surgical outpatient clinic than those not examined by FS (91.2%
vs. 82.8%). Approximately twice as many patients who did not receive a FS examination were referred to a
gastroenterology outpatient clinic as patients who did receive FS (9.5% vs. 5.1%).
Some major differences were observed in the symptomatic presentation of patients who had received a
FS examination compared with patients who had not (Table 34). Of the common symptoms, patients
who had received a FS examination were more likely to present with a CIBH (p < 0.001), rectal bleeding
(p = 0.001) and abdominal pain (p = 0.002). There was evidence to suggest that some of the less common
symptoms (and those not explicitly included in the NICE 2015 suspected cancer referral guidelines76),
TABLE 32 Diagnostic yield of distal and proximal cancers by sex, age group and whether or not the patient fits the































Total 7380 (100) 429 5.8 18 (16 to 19) 127 1.7 59 (49 to 70)
Men
Aged < 70 years
Symptoms meet
criteria for FS
770 (10.4) 62 8.1 13 (10 to 17) 2 0.3 385 (107 to 3178)
Symptoms do not
meet criteria for FS
735 (10.0) 43 5.9 18 (13 to 24) 14 1.9 53 (32 to 96)
Aged ≥ 70 years
Symptoms meet
criteria for FS
519 (7.0) 82 15.8 7 (6 to 8) 5 1.0 104 (45 to 319)
Symptoms do not
meet criteria for FS
1003 (13.6) 69 6.9 15 (12 to 19) 36 3.6 28 (21 to 40)
Women
Aged < 70 years
Symptoms meet
criteria for FS
1024 (13.9) 32 3.1 32 (23 to 47) 4 0.4 256 (101 to 939)
Symptoms do not
meet criteria for FS
1193 (16.2) 26 2.2 46 (32 to 71) 17 1.4 71 (45 to 121)
Aged ≥ 70 years
Symptoms meet
criteria for FS
719 (9.7) 60 8.3 12 (10 to 16) 3 0.4 240 (83 to 1162)
Symptoms do not
meet criteria for FS
1417 (19.2) 55 3.9 26 (20 to 35) 46 3.2 31 (24 to 42)
a The criteria for FS were presenting with either rectal bleeding in the absence of anaemia (defined as a Hb level of
< 13 g/dl in men or < 12 g/dl in women) or abdominal mass or presenting with a CIBH to looser stools and/or more
frequent defecation as the only symptom or sign.
b Five patients had both distal and proximal cancer diagnosed and the patients are included in both the distal and
proximal cancer columns.
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specifically bloating/flatulence and tiredness/weakness, were slightly more common in the cohort who had
not been examined by FS (p < 0.001 for both).
Fewer patients who were examined by FS, compared with those patients not examined by FS, had blood
test data available at presentation (p = 0.026) and fewer were reported to be anaemic (p < 0.001) (see
Table 34). By contrast, more patients who had received a FS examination had an abdominal (p < 0.001) or
a rectal (p = 0.007) mass.
The proportion of patients diagnosed with cancer was higher among those who had been examined by FS
than among those who had not (9.6% vs. 6.9%, respectively; p < 0.001) (Table 35). Of the 1483 patients
who were investigated with FS, 142 were diagnosed with CRC (see Table 35). Of these 142 patients, 112
(78.9%) were diagnosed with distal cancer. Patients examined by FS were also more likely to be diagnosed
with distal cancer (p = 0.001) than those who did not have a FS and there was some evidence to suggest
that this difference was attributable to a higher rate of rectal cancer in the cohort examined by FS (4.5%
vs. 2.4%). There was no difference in the rates of proximal cancer between the two subgroups (p = 0.22).













Men 3027 (41.0) 601 (40.5) 2426 (41.1)
Women 4353 (59.0) 882 (59.5) 3471 (58.9)
Age (years) 0.056
55–64 2410 (32.7) 472 (31.8) 1938 (32.9)
65–74 2739 (37.1) 594 (40.1) 2145 (36.4)
75–84 1898 (25.7) 357 (24.1) 1541 (26.1)
≥ 85 333 (4.5) 60 (4.0) 273 (4.6)
Route of referral < 0.001
Colorectal surgical outpatient clinic 6235 (84.5) 1353 (91.2) 4882 (82.8)
Gastroenterology outpatient clinic 638 (8.6) 76 (5.1) 562 (9.5)
Other outpatient clinic 50 (0.7) 6 (0.4) 44 (0.7)
Straight to test 396 (5.4) 39 (2.6) 357 (6.1)
Hospital admission 33 (0.4) 6 (0.4) 27 (0.5)
Not recorded 28 (0.4) 3 (0.2) 25 (0.4)
Urgency of referral < 0.001
Two-week wait 3976 (53.9) 748 (50.4) 3228 (54.7)
Urgent 1315 (17.8) 444 (29.9) 871 (14.8)
Soon 660 (8.9) 74 (5.0) 586 (9.9)
Routine 915 (12.4) 179 (12.1) 736 (12.5)
Not recorded 514 (7.0) 38 (2.6) 476 (8.1)
a p-value for the comparison of the cohort with FS performed with the cohort without FS performed.
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Rates of distal cancer were approximately twice as high in men as in women, whereas rates of proximal
cancer were similar between the sexes (Table 36). The yield of distal cancer increased with age; among
men and women aged ≥ 85 years, the proportion diagnosed with distal cancer (21.4% and 8.7%,
respectively) was more than twice that among those aged 55–64 years (9.0% and 4.1%, respectively).
The rate of proximal cancer was much lower than that of distal cancer but rates increased with increasing
age in both men and women.






(N= 1483), n (%)
Cohort without
FS performed
(N= 5897), n (%) p-valuea
Symptoms
CIBH 5382 (72.9) 1133 (76.4) 4249 (72.1) < 0.001
Looser and/or more frequent 2862 (38.8) 575 (38.8) 2287 (38.8)
Harder and/or less frequent 865 (11.7) 139 (9.4) 726 (12.3)
Variable 648 (8.8) 132 (8.9) 516 (8.8)
Unspecified 1007 (13.6) 287 (19.4) 720 (12.2)
Rectal bleeding 2773 (37.6) 612 (41.3) 2161 (36.6) 0.001
Abdominal pain 2126 (28.8) 476 (32.1) 1650 (28.0) 0.002
Weight loss 1148 (15.6) 221 (14.9) 927 (15.7) 0.44
Bloating/flatulence 203 (2.8) 21 (1.4) 182 (3.1) < 0.001
Tiredness/weakness 152 (2.1) 14 (0.9) 138 (2.3) < 0.001
Anal symptoms 97 (1.3) 17 (1.2) 80 (1.4) 0.53
Nausea/vomiting 44 (0.6) 7 (0.5) 37 (0.6) 0.49
Back pain 13 (0.2) 1 (0.1) 12 (0.2) 0.49
Upper GI symptoms 10 (0.1) 1 (0.1) 9 (0.2) 0.70
Signs/indications
Anaemia
Blood test data collected 4741 (62.2) 916 (61.8) 3825 (64.9) 0.026
Anaemiab 1888 (25.6) 318 (21.4) 1570 (26.6) < 0.001
Abdominal mass 216 (2.9) 63 (4.3) 153 (2.6) < 0.001
Rectal mass 165 (2.2) 47 (3.2) 118 (2.0) 0.007
FOBt positive 113 (1.5) 18 (1.2) 95 (1.6) 0.27
Family history 117 (1.6) 15 (1.0) 102 (1.7) 0.048
History of polyps 23 (0.3) 1 (0.1) 22 (0.4) 0.067
Other signsc 16 (0.2) 2 (0.1) 14 (0.2) 0.75
a p-value for the comparison of the cohort with FS performed with the cohort without FS performed.
b In patients with blood test data, anaemia was determined only by blood test results and was defined here as a Hb level
of < 13 g/dl in men or < 12 g/dl in women. In patients without blood test data, anaemia was determined from
indications at referral and a patient was defined as having anaemia if anaemia was mentioned as a reason for referral.
c Other signs include the presence of cancer antibodies, elevated C-reactive protein or liver problems.
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Flexible sigmoidoscopy miss rates for distal cancers
Of the 112 patients diagnosed with distal cancer who had been examined by FS, most (90.2%) had cancer
diagnosed by FS (Table 37). Of the 11 distal cancers (9.8%) not diagnosed at FS, eight might have been
found if current practice was applied, as patients in whom FS was incomplete or in whom a lesion was
detected would have gone on to receive a repeat examination and/or a WCI. Only in the three patients
with a ‘complete and normal’ FS examination would cancer have been missed by FS (miss rate 2.7%).






(N= 1483), n (%)
Cohort without
FS performed
(N= 5897), n (%) p-valuea
Total patients with cancer 551b (7.5) 142c (9.6) 409d (6.9) < 0.001
Distal cancers
Total patients with distal cancer 429b (5.8) 112c (7.6) 317d (5.4) 0.001
Anus 10 (0.1) 3 (0.2) 7 (0.1)
Rectum 210 (2.8) 66 (4.5) 144 (2.4)
Rectosigmoid 57 (0.8) 11 (0.7) 46 (0.8)
Sigmoid colon 146 (2.0) 31 (2.1) 115 (2.0)
Descending colon 8 (0.1) 2 (0.1) 6 (0.1)
Distal colorectum
(no further specification)
4 (0.1) 3 (0.2) 1 (0.0)
Proximal cancers
Total patients with proximal cancer 127b (1.7) 31c (2.1) 96d (1.6) 0.22
Splenic flexure 9 (0.1) 1 (0.1) 8 (0.1)
Transverse colon 18 (0.2) 6 (0.4) 12 (0.2)
Hepatic flexure 14 (0.2) 3 (0.2) 11 (0.2)
Ascending colon 36 (0.5) 9 (0.6) 27 (0.5)
Caecum 53 (0.7) 12 (0.8) 41 (0.7)
a p-value for the comparison of the cohort with FS performed with the cohort without FS performed.
b In total, 565 cancers were diagnosed in 551 patients; five patients had both distal and proximal cancer, three patients
had two proximal cancers and six patients had two distal cancers.
c In total, 147 cancers were diagnosed in 142 patients; one patient had both distal and proximal cancer and four patients
had two distal cancers.
d In total, 418 cancers were diagnosed in 409 patients; four patients had both distal and proximal cancer, three patients
had two proximal cancers and two patients had two distal cancers.
TABLE 36 Diagnoses of CRC in 1483 patients with FS performed at the time of referral by subsite, sex and
age group
CRC subsite

































Distal 18 (9.0) 31 (12.8) 17 (11.8) 3 (21.4) 11 (4.1) 18 (5.1) 10 (4.7) 4 (8.7)
Proximal 1 (0.5) 4 (1.7) 8 (5.6) 0 (0) 2 (0.7) 6 (1.7) 8 (3.8) 2 (4.3)
RESULTS
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There were 31 patients who were initially examined by FS and subsequently diagnosed with proximal
cancer. Two-thirds of these (n = 22) were diagnosed after a ‘complete and normal’ FS examination and
would not have gone on to have a WCI after this outcome, unless other diagnostic indicators were present.
Flexible sigmoidoscopy miss rates for proximal and distal colorectal cancer
by clinical features
Approximately one in four patients (n = 359) who underwent FS at baseline presented with anaemia
and/or an abdominal mass, of whom slightly more were diagnosed with proximal than with distal cancer
(n = 25 vs. 23; Table 38). Of the 23 patients diagnosed with distal cancer, 18 (78.3%) were diagnosed in
those in whom cancer had been suspected at FS and four (17.4%) were diagnosed in patients who had an
incomplete examination. Only one patient with distal cancer was diagnosed after a ‘complete and normal’
FS examination (potential miss rate 4%). Notably, 19 out of 25 patients (76.0%) with proximal cancer had
a ‘normal and complete’ FS examination.
Half of the patients diagnosed with cancer (53.5%, 76/142) who were examined by FS presented with
the symptom profile of rectal bleeding without anaemia or an abdominal mass (see Table 38). In this
group, 73 (96.0%) had distal cancer and the large majority of these cancers (n = 69) were diagnosed at FS.
Only three patients with this symptom combination were diagnosed with proximal cancer after a FS
examination, and two of these patients had findings at FS that might have warranted a WCI.
In total, 39.0% (n = 578) of patients examined by FS presented with a CIBH (of any subtype) without rectal
bleeding, anaemia or an abdominal mass, 18 of whom were diagnosed with cancer. The majority (83.3%,
n = 15) had distal cancer diagnosed. Only three patients overall were diagnosed with proximal cancer in
this group, all of whom had a CIBH to subtypes other than looser and/or more frequent stools. One
patient with a CIBH was diagnosed with proximal and distal cancer after FS examination, although this
patient also had a large lesion detected at FS, which might have warranted a WCI; the remaining two
proximal cancers were diagnosed after complete and normal FS examinations. Fewer patients who
presented with a CIBH without other common NICE referral criteria symptoms/clinical signs (anaemia, an
abdominal mass or rectal bleeding) were diagnosed with cancer (see Table 38).






distal cancer,a n (%)
Patients diagnosed with
proximal cancer,a n (%)
Total 1483 (100) 112b (7.6) 31b (2.1)
Cancer suspected 108 (7.3) 101 (93.5) 1 (0.9)
≥ 10-mm lesion detected 54 (3.6) 2b (3.7) 3b (5.6)
≥ 3 lesions detected 10 (0.7) 0 (0) 1 (10.0)
Incomplete owing to pain 158 (10.7) 2 (1.3) 1 (0.6)
Incomplete owing to faeces 157 (10.6) 3 (1.9) 2 (1.3)
Incomplete owing to technical issuesc 50 (3.4) 1 (2.0) 1 (2.0)
Incomplete for unknown reason 8 (0.5) 0 (0) 0 (0)
Complete and normal 938 (63.3) 3 (0.3) 22 (2.3)
a Includes all included CRCs diagnosed within 3 years of referral.
b One patient had both distal and proximal cancer diagnosed and each patient is included in both the distal and proximal
cancer columns.
c Includes issues related to looping, strictures, angulation and problems with the scope.
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Rectal bleeding, no anaemiaa
or abdominal mass
CIBH to looser and/or more
frequent, no anaemia,a
abdominal mass or rectal
bleeding
CIBH to other than looser
and/or more frequent, no
anaemia,a abdominal mass
or rectal bleeding
Abdominal pain or weight
loss, no anaemia,a abdominal
mass, rectal bleeding or CIBH






































Total 1483 359 (24.2) 23 25 493 (33.2) 73 3 321 (21.6) 6 0 257 (17.3) 9c 3c 44 (3.0) 0 0 9 (0.6) 1 0
Cancer
suspected
108 22 (20.4) 18 0 71 (65.7) 69 1 7 (6.5) 6 0 7 (6.5) 7 0 0 (0.0) 0 0 1 (0.9) 1 0
≥ 10-mm lesion
detected
54 10 (18.5) 0 2 33 (61.1) 1 0 5 (9.3) 0 0 6 (11.1) 1c 1c 0 (0.0) 0 0 0 (0.0) 0 0
≥ 3 lesions
detected
10 0 (0.0) 0 0 5 (50.0) 0 1 3 (30.0) 0 0 1 (10.0) 0 0 1 (10.0) 0 0 0 (0.0) 0 0
Incomplete
owing to pain
158 43 (27.2) 2 1 43 (27.2) 0 0 39 (24.7) 0 0 29 (18.4) 0 0 4 (2.5) 0 0 0 (0.0) 0 0
Incomplete
owing to faeces








8 3 (37.5) 0 0 2 (25.0) 0 0 1 (12.5) 0 0 2 (25.0) 0 0 0 (0.0) 0 0 0 (0.0) 0 0
Complete and
normal
938 214 (22.8) 1 19 275 (29.3) 2 1 229 (24.4) 0 0 181 (19.3) 0 2 32 (3.4) 0 0 7 (0.7) 0 0
Shading corresponds to groups identified as low risk for proximal cancer and possibly suitable for referral for FS as first-line investigation.
a In patients with blood test data, anaemia was determined only by blood test results and was defined here as a Hb level of < 13 g/dl in men or < 12 g/dl in women. In patients without
blood test data, anaemia was determined from indications at referral and a patient was defined as having anaemia if anaemia was mentioned as a reason for referral.
b Includes all included CRCs diagnosed within 3 years of referral.
c One patient had both distal and proximal cancer diagnosed and this patient is included in both the distal and proximal cancer columns.













Approximately 3% (n = 44) of patients examined by FS presented with abdominal pain/weight loss
(without anaemia, an abdominal mass, rectal bleeding or a CIBH) (see Table 38). No patients with this
symptom profile were diagnosed with cancer.
Patient and cancer profiles of distal cancers missed at initial flexible
sigmoidoscopy examination
Of the 11 patients subsequently diagnosed with distal cancer whose diagnosis was missed at FS, six
(54.5%) were men and seven (63.6%) were aged ≥ 73 years (Table 39). The majority of these patients
(n = 8) had cancer in the sigmoid colon. One male patient was subsequently diagnosed with a large
tumour (90 mm) in the sigmoid colon after a FS examination that was incomplete owing to the presence
of faeces. Distal cancers in two female patients that were missed at FS were also subsequently missed at
WCI (CT colonography).
TABLE 39 Distal cancers not seen at FS performed at the time of referral in 1483 patients
Patient Sex Age (years) Cancer site Cancer size (mm) Findings at FS
1 Male 56 Distal Unknown Incomplete owing to faeces
2 Male 63 SC 90 Incomplete owing to faeces
3 Male 63 SC and DC 50 (annular); unknown Incomplete owing to faeces
4 Male 73 SC 52 Incomplete owing to pain
5 Male 78 SC 70 Complete and normal
6 Male 78 DC and TC Unknown 10-mm polyp in SC
7 Female 59 SC Unknown ≥ 10-mm polypoidal swelling in
RM and diagnosed proctitis
8 Female 73 SC Unknown Incomplete as could not advance
scope, diverticular disease
9 Female 74 RM Unknown Complete and normal
10 Female 74 SC Unknown Complete and normal. Cancer
also missed by CT colonography
11 Female 80 SC 50 Incomplete owing to pain. Cancer
also missed by CT colonography
DC, descending colon; RM, rectum; SC, sigmoid colon; TC, transverse colon.
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I t is widely recognised that the frequency of particular signs or symptoms differs between patients withproximal and distal CRC. Patients with proximal CRC more frequently present with anaemia, whereas
patients with distal CRC are more likely to present with rectal bleeding or a CIBH.33,35,37,54,58,62,66,67,77–82
There have been a number of attempts to use clinical features at presentation to inform decisions about
the most appropriate diagnostic investigation. An early attempt was that of Majumdar et al.,37 who
created an algorithm to predict distal location of CRC based on the presence of anaemia, rectal bleeding,
constipation, anorexia, vomiting, nausea, fatigue and abdominal pain.37
More recent strategies have focused on IDA, abdominal mass, a CIBH and rectal bleeding. A number of
authors have found that IDA and abdominal mass are strongly associated with proximal cancer and that
patients without either of these two signs are unlikely to have proximal cancer.29,32,33,83 Others have noted
that rectal bleeding and/or a CIBH are predominantly distal symptoms and proximal cancer is only rarely
diagnosed in patients with these symptoms, particularly in the absence of other signs or symptoms.29–31
However, the suitability of these symptom combinations to identify patients with low risk of proximal
cancer, in whom WCI could be avoided, is not fully agreed,34,36 and the current NICE guideline
recommends WCI for all patients referred to secondary care with symptoms and signs indicative of CRC.3
The study by Thompson et al.,33 which is the largest to date and which our study aimed to validate, collected
data prospectively on 16,433 patients newly referred to a colorectal clinic in Portsmouth between 1986 and
2001 with clinical features suggestive of CRC. In that study the diagnostic yield for proximal cancer in patients
without IDA or an abdominal mass was 0.2% (37/15,829), with the proportion of cancers located proximally
in this symptom group being 4.7%. Similarly, in patients without IDA or an abdominal mass who presented
with rectal bleeding or a CIBH alone, the diagnostic yield for proximal cancer was only 0.2% (21/11,867) and
only 3.1% (21/671) of cancers in this symptom group were proximally located.
In the study by Thompson et al.,33 the diagnostic yield for proximal cancer was slightly higher in those with
a CIBH to less frequent stools than in those who experienced a CIBH to more frequent stools (0.7% vs.
0.2%, respectively). Furthermore, the proportion of cancers that were proximal in those with a CIBH to less
frequent stools was substantially higher (25.0%, 1/4) than in in those with a CIBH to more frequent stools
(3.1%, 2/64).33 FS was the initial investigation in 98.9% of patients, and the diagnostic yield of WCI after
FS was low (2.3%). These findings led the authors to recommend FS for investigation of patients without
IDA or an abdominal mass, together with careful treat-watch-and-wait diagnostic strategies and WCI for
patients with persistent or recurrent symptoms.
We studied an independent cohort of 7380 patients with clinical features suggestive of CRC who were
referred to 21 hospitals in England between 2004 and 2007. We confirmed that for a proportion of patients
with specific symptoms alone, an examination of the distal colorectum only, rather than a WCI, may be a
safe option for the diagnosis or exclusion of CRC. In our study, we focused initially on the proportion of
diagnosed cancers that were located distally as a measure of the likely sensitivity of a distal examination for
detection of cancer in patients with a particular symptom profile. Using this method, we showed that a high
proportion (41.4%) of cancers diagnosed in patients with anaemia (Hb < 13 g/dl in men or < 12 g/dl in
women) or an abdominal mass were located in the proximal colon and that WCI is therefore necessary for
these patients. The proportion of diagnosed cancers that were proximal was even higher in patients with
both anaemia and an abdominal mass (55.3%). By contrast, we identified two symptomatic patient groups
(without anaemia or an abdominal mass) for whom FS would be an acceptable examination. These were:
1. patients with rectal bleeding either as a single symptom or in combination with other symptoms,
including a CIBH
2. patients with a CIBH to looser and/or more frequent stools as a single symptom.
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Among patients with rectal bleeding and no anaemia or abdominal mass, 94.0% of cancers were located
distally. Having additional symptoms such as a CIBH, abdominal pain or weight loss did not increase the
proportion of proximal cancers, suggesting that the presence of rectal bleeding is a strong indicator of a
distal location (see Table 29). In this group, only 14 proximal cancers were diagnosed in 2196 patients
(diagnostic yield 0.6%), suggesting that 157 WCIs would have been required to detect a single
proximal cancer.
Patients with a CIBH without rectal bleeding (and no anaemia or abdominal mass) were a more
heterogeneous group, in whom, overall, 20.0% of cancers were located proximally. However, of the
15 cancers diagnosed in those with a CIBH to looser and/or more frequent stools as a single symptom,
none was a proximal cancer.
Patients without anaemia or an abdominal mass but with rectal bleeding constituted 29.8% of the cohort
(2196/7380), while those who presented with a CIBH as a single symptom to looser and/or more frequent
stools constituted 11.3% of the cohort (836/7380). Therefore, for approximately 40% of patients in our
cohort, investigation by FS alone might have been sufficient.
Our findings are supported by a number of studies that have looked at either the proportion of cancers
that are proximal according to clinical features at presentation or the proportion of proximal cancers
diagnosed in prospectively collected series of patients with rectal bleeding or a CIBH referred under the
2-week wait pathway. Kent et al.31 audited all CRCs diagnosed over a 2-year period and found that, out
of 45 patients with proximal cancers, 41 presented with anaemia or an abdominal mass, four presented
with a CIBH (to unspecified frequency) and abdominal pain and none presented with a CIBH and/or rectal
bleeding as sole symptoms. In a similar audit of cancers diagnosed over a 2-year period, Ingham Clark et al.30
found that, out of 38 patients with proximal cancers, none presented with rectal bleeding and/or a CIBH
alone. Ingham Clark et al.30 also audited all colonoscopies performed in 2010 to investigate rectal bleeding
and/or a CIBH. Of 21 CRCs diagnosed, only two were located proximal to the splenic flexure, and in both
cases the symptoms were accompanied by abdominal pain. In an audit by Royle et al.32 of 1690 patients
referred to a rapid access FS with ‘red-flag’ symptoms, but no anaemia or abdominal mass, only two proximal
cancers (0.24%) were diagnosed following a cancer-free FS. Similarly, Couch et al.35 reported that in 968
patients referred from primary care for colonoscopy for the investigation of ‘red-flag’ symptoms, none of the
17 cancers located proximal to the splenic flexure were diagnosed in patients with rectal bleeding. In the series
reported by Bhangu et al.,34 of 85 patients referred to a 2-week wait clinic with either rectal bleeding, a CIBH
or abdominal pain, 13 (15.3%) were diagnosed with proximal cancer.34 This unacceptably high figure may
have been the result of inclusion of abdominal pain, which our present study suggests could be a symptom
of proximal cancer. These studies support the theoretical use of FS for patients with rectal bleeding and/or a
CIBH alone, without anaemia or an abdominal mass, but are more equivocal about the most appropriate
investigation for patients with a CIBH without rectal bleeding. However, most studies do not draw a distinction
between a CIBH to looser and/or more frequent stools, which seems to be a distal symptom, and a CIBH to
harder and/or less frequent stools, which can also be a symptom of proximal cancer. These previous studies
also confirm that if a CIBH is accompanied by abdominal pain, then a WCI is needed.
Sensitivity and specificity of anaemia and iron deficiency
anaemia for proximal cancer
We have confirmed the findings of others that anaemia with and without evidence of IDA (and/or
abdominal mass) confers a high yield of cancer in patients referred to secondary care.33,34,84,85 Although
anaemia is seen in both proximal and distal disease, it is the most frequent clinical feature in proximal
cancers, symptoms of which tend to be vague. Anaemia has therefore been used to define a population of
patients in whom a WCI is warranted and, conversely, its absence has been used to define patients in
whom FS might be safe.33
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However, there is no consensus on the precise definition of anaemia that should be used. To address this,
we investigated the influence of varying definitions of anaemia and IDA on outcomes; we investigated
different diagnostic thresholds with four definitions of anaemia/IDA in analyses. The definitions used were
‘broad anaemia’, ‘strict anaemia’, ‘broad IDA’ and ‘strict IDA’, which incorporated Hb, MCV and/or ferritin
values (see Table 5). Of the 96 proximal cancers diagnosed in patients with blood test data in the present
study, 77 (80.2%) were found in the 1659 patients with anaemia defined by the broadest definition,
60 (62.5%) were found in 875 patients with anaemia by the strict definition, 48 (50.0%) were found in 567
patients with IDA by the broad definition and 20 (20.8%) were found in 172 patients with IDA according to
the most strict definition. Thus, widening the definition of anaemia increased the sensitivity of this clinical
sign for proximal cancer. Broad definition anaemia is therefore likely to be the most diagnostically useful for
excluding proximal cancer. The downside of using the broadest definition of anaemia is decreased specificity.
Widening the definition from the strictest to the broadest definition of anaemia decreased diagnostic yields
from 8.5% with IDA (broad definition) to 4.6% (for the broad definition of anaemia). However, even with
the broadest definition, anaemia was the feature with the highest yield for proximal cancer of any symptom
or sign. As anaemia is also found in patients with distal cancer, the overall yield of CRC (proximal or distal) in
those with anaemia was 10.9%, with a number needed to be examined to detect a CRC at any site of only
10. Other studies investigated the associations between anaemia/IDA and CRC site using varying definitions
of anaemia/IDA, based on local laboratory thresholds or national/international guidelines;29,32,33,37 however, in
some instances, the definitions used are not clear.30,31,35 We have demonstrated the impact of using different
definitions for anaemia/IDA on diagnostic study outcomes. In the Thompson et al.33 series, patients were
considered to have IDA on the basis of low Hb (reference range 13–18 g/dl men and 12–16 g/dl women) and
low MCV (reference range 80–95 fl). This is most comparable with the broad IDA definition used in our
present study.
Sensitivity of flexible sigmoidoscopy in diagnosis of
distal cancer
Although we have shown that certain groups of patients are more likely to have distal cancer, there are
various reasons why cancers may not be detected at FS. First, we have defined a distal cancer as one that
occurs distal to the splenic flexure. However, one problem with FS is that there are no landmarks to
determine the anatomical site reached by the instrument. The length of scope inserted is also not a good
marker because of the propensity for looping in the sigmoid colon. However, using magnetic endoscopic
imaging, which permits visualisation of the anatomical location of the endoscope tip, Painter et al.86 found
that the splenic flexure was not reached in 60.7% of 117 FS procedures and the sigmoid colon/descending
colon junction was not reached in 24.8% of procedures. Similar findings were also reported by others.87,88
In our cohort, 11 out of 112 (9.8%) distal cancers were not diagnosed at FS, although only three of these
cancers were diagnosed following a FS that was reported to be complete and normal. In two patients, a
large (≥ 10 mm) distal lesion that would have warranted WCI was detected, and in six patients FS was
incomplete owing to pain or the presence of faeces.
In other series of patients undergoing FS as their initial investigation, few have reported the miss rate of
distal cancer. In the Thompson et al.33 series, 786 out of 813 distal cancers (96.7%) were detected at the
initial FS and a further 22 were diagnosed at the subsequent WCI, which in 19 cases was carried out
because FS was incomplete, in two cases was carried out because of suspicious symptoms and in one case
was carried out because of a family history of bowel cancer. A further five cancers were subsequently
diagnosed during 3 years of follow-up among patients who did not have further WCI, giving a miss rate of
0.6%. In a more recent series of 1690 patients referred to a rapid-access, straight-to-test FS clinic for
symptomatic urgent symptoms (excluding a right-sided mass or IDA), a distal cancer was diagnosed in 82
patients at FS, and no patient with a cancer-free FS who had a subsequent WCI was found to have cancer
within 3 years.32 In a series of 591 patients referred to a rapid-access FS clinic in 2006, Lim et al.89 reported
that 34 distal cancers were diagnosed, of which 32 (94.1%) were diagnosed at FS. These findings conflict
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with a study of the odds of an interval distal CRC after FS compared with colonoscopy among 15,484 older
patients in the USA.90 The study used the Surveillance, Epidemiology and End-Results-Medicare linked
database, and an interval CRC was defined as one diagnosed between 6 and 36 months after lower
endoscopy. The authors found that 8.8% of CRCs diagnosed after FS were interval, compared with 2.5%
after colonoscopy (odds ratio 3.52). The authors speculated that the increased rate might be related to
differences in bowel preparation quality, sedation use or depth of insertion. However, it was also noted that
an incomplete colonoscopy not reaching the splenic flexure is billed to Medicare as FS, which could be a
potential bias. Procedures performed in an office setting are more likely to be incomplete and older adults
are less likely to be offered a follow-up colonoscopy.91–93
Thus, despite FS not reaching the splenic flexure in around 60% of patients (according to literature from
the 1980s and 1990s),87–89 few distal cancers are missed when the examination is declared to be normal
and complete. Only 8 of the 551 cancers diagnosed in our series (1.5%) were located in the descending
colon (see Table 3), the distal segment least likely to be examined at FS. Moreover, only two of these
descending colon cancers had the symptom profile that would fit suitability for FS.
Whole-colon investigations performed after flexible sigmoidoscopy
A proportion of patients who have FS at their initial investigation will have a subsequent WCI. In some
series this proportion is as high as 70%.32,89 In the Thompson et al.33 series, 34.8% of patients (5665/
16,256) had WCI after FS. In studies in lower-risk patients, or when criteria for WCI referral after FS were
more tightly controlled, referral rates were slightly lower, ranging from 16% to 31%.71,94,95 It is not
possible to determine the proportion of patients referred for WCI after FS in the SOCCER cohort, as
patients were eligible for the SIGGAR trials on the basis that they required a WCI. Very few studies report
reasons for referral for WCI after FS, but clearly this is an important question, as it profoundly affects the
cost-effectiveness of offering FS. In the few studies that do provide details, the reasons provided include
the presence of distal pathology (neoplastic and non-neoplastic),71,89,94–97 suboptimal bowel preparation
and/or incomplete FS,89,94,95,97 symptoms not adequately explained at FS32,57,97 and the presence of
symptoms/signs (anaemia, abdominal pain, weight loss and faecal occult blood) that are suggestive of
proximal pathology.89,95,96
In the Thompson et al.33 series, the yield of proximal cancer in patients receiving WCI after FS was
particularly low in patients with distal symptoms when FS yielded no clear indication for further
investigation. Similarly, in the SOCCER series only three proximal cancers were diagnosed in this scenario
(see Table 38). Very few studies have looked at the yield of benign proximal pathology (neoplastic or
non-neoplastic) from WCI after FS in patients with distal symptoms;32,71 however, this can be estimated
from studies in patients with distal symptoms having WCI in which isolated proximal pathology that would
not be detected by FS is reported.98,99 In the SOCCER cohort, 1057 patients had a colonoscopy as part of
the SIGGAR trials and 36 were diagnosed with colitis; however, only three had isolated colitis in the
proximal colon. Just one of these patients had a CIBH to looser and/or more frequent stools as their only
symptom; the remaining two presented with anaemia or weight loss (data not presented). We can find no
other studies that report isolated benign proximal findings in patients with rectal bleeding and/or a CIBH
but no proximal symptom or signs. One study of 1766 patients undergoing colonoscopy for rectal bleeding
found non-malignant proximal pathology (including diverticular disease, polyps and colitis) in 53.0% of
patients overall and in 9.5% of patients in whom no significant distal pathology had been found.98 In this
series, patients with abdominal pain and some right-sided symptoms were excluded but those with
anaemia were not. In the only study to examine the additional yield of colonoscopy over FS in patients
with diarrhoea, the diagnostic yield for isolated inflammatory bowel disease and microscopic colitis in the
proximal colon was 1.6%.99 This study was in a young cohort (aged ≤ 50 years) of 615 patients, 62.1% of
whom presented with chronic diarrhoea. Although patients with IDA or rectal bleeding were excluded,
some presented with abdominal pain.
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Another potential reason for performing WCI after FS is to complete an examination that had to be
terminated because of pain or poor bowel preparation. FS is usually performed without intravenous
sedation or pain relief and a proportion of patients may not tolerate the procedure. In our series, pain led
to termination of the procedure in 10.7% of patients (see Table 37). Some endoscopy units now offer a
50 : 50 mix of nitrous oxide and air (Entonox®, BOC Healthcare, Manchester, UK) to help to manage
procedural pain. An advantage of Entonox is that patients recover rapidly and driving ability is not
impaired.100 To achieve clearance of the sigmoid colon and rectum, it is usual to use a single phosphate
enema, either self-administered by the patient at home33,89 or administered in the endoscopy unit around
1 hour prior to the procedure.32,33,89,101 However, the rate of incomplete FS owing to poor bowel preparation
in symptomatic series varies from 4% to 9%.32,71,101,102 In our series it was 10.6% (157/1483; see Table 37).
For patients found to have suboptimal bowel preparation at FS, some units now administer a second enema
via the endoscope and repeat the procedure after the patient has opened their bowels. There are no
published studies on whether the use of Entonox for patients experiencing discomfort, or the administration
of a second enema when the first one has not achieved adequate distal cleansing, has increased completion
rates for FS.
Strengths and limitations
This study has a number of strengths. It was a multicentre study of > 7000 patients for whom detailed data
concerning clinical features at presentation and diagnoses were collected. Most previous studies examining
the associations between symptoms and risks of distal and proximal cancer in the UK health-care setting
have been single-site studies and/or involved small numbers of patients.29–34,36 In addition, we have applied
four definitions of anaemia in the data analyses, which has provided deeper insight into the diagnostic
implications of anaemia in CRC. However, this study also has some limitations. The impact of selection bias
in the SOCCER study was minimised through consecutive patient enrolment, the multicentre setting and the
inclusion of patients who had originally been excluded from the SIGGAR trials; however, some residual
impact is likely to remain and the degree to which this has had an impact on the findings has not been
quantified. For example, this cohort is not fully representative of all patients being assessed for symptoms
suggestive of CRC in secondary care as only patients aged > 55 years were included.
The SIGGAR trials were not initially designed to answer the question of whether or not FS is suitable for a
certain subset of patients as defined by presenting symptom. For this reason, the trial pro forma did not
include tick boxes for a number of clinical features. Instead, many symptoms had to be extracted from
free-text fields, which may have introduced information bias. Furthermore, the eligibility criteria for SIGGAR
meant that patients were recruited if they were deemed to need a WCI. The exclusion of participants who
were not deemed to need a WCI may have inflated the diagnostic yields for proximal cancer in our study.
In England, up to one-quarter of all CRCs present as an emergency103 and it has been demonstrated that
proximal cancers are more likely than distal cancer to present as an emergency.42,43 Clearly, the patients
with proximal cancer included in the study presented here are not representative of all patients with
proximal cancer as most were recruited via outpatient clinics. However, the findings of the SOCCER study
do apply to non-emergency patients (i.e. the large majority) when there is scope to improve outcomes for
those with CRC by ensuring that they receive effective and efficient diagnostic investigation(s).
The generalisability of our findings may be affected by changes in the population presenting to secondary
care with suspected CRC that have occurred since the trial ended in 2007 or that may occur in the future.
New NICE referral guidelines were introduced in 2015,46 which are likely to alter the population of patients
referred for potential CRC by GPs. New recommendations include the use of FOBt in primary care.
Furthermore, the introduction of FS screening (bowel scope) and accompanying accreditation of bowel
scope screening endoscopists may influence the quality of FSs performed within the NHS. Other potential
factors that may influence the generalisability of our findings include the introduction of screening using
FOBt in 2008 and an increasingly ageing population.
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We have made some assumptions for conclusions relating to the suitability of FS as an initial investigation.
We have assumed that the diagnostic accuracy of FS for distal cancer is 100% and that colonoscopy
detects 100% of distal and proximal cancers, which does not reflect clinical practice. We were unable to
assess the quality of FS procedures because it appears that information on the quality of bowel preparation
and the completeness of examination is not routinely recorded.
Conclusions
We corroborated previous findings and demonstrated that the proportion of CRC diagnoses that are
proximally located in patients without anaemia or abdominal mass is low in those with:
l rectal bleeding as a single symptom or in combination with other symptoms
l a CIBH to looser stools and/or more frequent defecation as a single symptom.
Flexible sigmoidoscopy alone should be a safe examination in these two groups of patients. Rapid-access
clinics offering FS should be a safe and efficient mechanism to diagnose or exclude CRC in the many
patients with these symptoms.
A high proportion of CRCs diagnosed in patients with anaemia, abdominal mass or other symptoms or
signs, such as abdominal pain, weight loss or a CIBH to less frequent stools, were located in the proximal
colon, and a WCI is necessary for these patients.
Implications for practice
The risk of CRC in primary care by presenting clinical features was the subject of a review and update by
the NICE guidelines in 2015.76 To improve the sensitivity of the referral pathway for suspected CRC, the
recommended referral threshold was set at a positive predictive value of 3%, where previously thresholds
had been disparate but generally > 5%.46 It was acknowledged that, owing to the common and non-
specific nature of CRC symptoms, this would correspondingly lower the specificity of referral but the
3% positive predictive value threshold was considered the level at which potential benefits generally
outweighed potential risks. It is inevitable, however, that the lowered referral threshold for suspected CRC
will result in many more patients having further diagnostic investigations but, ultimately, not being found
to have this disease.104 This study adds to the body of evidence that supports the selective use of FS as an
initial investigation to confirm or exclude CRC diagnosis in clinical practice. It is expected that reducing
the number of WCIs performed in the NHS could reduce both the patient and health service diagnostic
burdens for this disease, which will inevitably become more pressing if specificity of referral pathways
is reduced. At present, despite the accumulating evidence supporting symptom-based tailoring of
initial investigations for CRC, and the fact that FS is being employed in clinical practice, there are no
recommendations for this practice in the current NICE guideline.3
Recommendations for research
This study was unable to provide answers to some questions, which we believe may be priorities for future
research. Avenues for future research might include:
l A cost-effectiveness analysis of symptom-based tailoring of diagnostic investigations for CRC. Such an
analysis should incorporate both neoplastic and non-neoplastic disease outcomes.
l Investigating the age/sex/symptom profile of all consecutive patients referred to hospital with the lower
threshold (positive predictive value 3%) given in the NICE 2015 suspected cancer referral guidelines;76 doing
so would answer the question of the potential role of FS in terms of reducing the requirement for a WCI.
l Assessing the proportion of FS examinations for which pain or poor bowel preparation are reported,
how many of these result in an incomplete examination, and the local measures (e.g. use of Entonox,
administering a second enema and repeating the examination after a short delay) used to increase
completion rates for FS examinations. In addition, assessing any improvement in diagnostic yields, both
for cancer and significant polyps, achieved as a result of these additional measures.
DISCUSSION
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Appendix 1 Participating hospitals




Royal United Hospital, Bath Royal United Hospitals Bath NHS Foundation Trust 446
Bradford Royal Infirmary Bradford Teaching Hospitals NHS Foundation Trust 729
Queen Elizabeth Hospital, Birmingham University Hospitals Birmingham NHS Foundation Trust 414
Charing Cross Hospital and Hammersmith
Hospital
Imperial College Healthcare NHS Trust 271
Leighton Hospital, Crewe Mid Cheshire Hospitals NHS Foundation Trust 433
Royal Cornwall Hospital, Truro Royal Cornwall Hospitals NHS Trust 521
Frimley Park Hospital, Camberley Frimley Health NHS Foundation Trust 52
Royal Lancaster Infirmary/Furness General
Hospital
University Hospitals of Morecambe Bay NHS
Foundation Trust
518
Queen’s Medical Centre, Nottingham/
Nottingham City Hospital
Nottingham University Hospitals NHS Trust 561
University Hospital of North Tees,
Stockton-on-Tees
North Tees and Hartlepool Hospitals NHS Foundation
Trust
64
The Royal Oldham Hospital Pennine Acute Hospitals NHS Trust 412
John Radcliffe Hospital, Oxford Oxford University Hospitals NHS Foundation Trust 150
St Mary’s Hospital, Paddington Imperial College Healthcare NHS Trust 225
Derriford Hospital, Plymouth Plymouth Hospitals NHS Trust 242
Queen Alexandra Hospital, Portsmouth Portsmouth Hospitals NHS Trust 810
St Mark’s Hospital, Harrow London North West Healthcare NHS Trust 1399
Withington Community Hospital/Wythenshawe
Hospital, Manchester
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Appendix 2 SIGGAR trial eligibility
TABLE 41 Reasons patients assessed for eligibility in the SIGGAR trials were not randomised
Reason n (%)
Clinician-declined consent 2176 (71.7)
CRC already diagnosed 56 (1.8)
Other cancer already diagnosed 69 (2.3)
Clinician requested specific procedure
Colonoscopy 731 (24.1)
CT colonography 303 (10.0)
FS 230 (7.6)
Oesophagogastroduodenoscopy 218 (7.2)
Barium enema 19 (0.6)
Ultrasound 16 (0.5)
Magnetic resonance imaging 5 (0.2)
Requested procedure unknown 39 (1.3)
Clinical situation too urgent or waiting list too long 52 (1.7)
Patient unfit for whole colon examination 215 (7.1)
Patient unable to give informed consent 75 (2.5)
No reason given 148 (4.9)
Patient-declined consent 834 (27.5)
Patient requested specific procedure
Colonoscopy 15 (0.5)
CT colonography 3 (0.1)
Barium enema 2 (0.07)
Requested procedure unknown 128 (4.2)
Patient wanted to avoid specific procedure
CT colonography because claustrophobic 13 (0.4)
CT colonography for other reasons 2 (0.07)
Colonoscopy 1 (0.03)
Barium enema 1 (0.03)
Patient had difficulty comprehending 84 (2.8)
Patient died before consent obtained 2 (0.07)
No reason given 583 (19.2)
Reason for exclusion unknown 26 (0.9)
Total excluded patients 3036
Source: reproduced with permission from Atkin et al.18 and Halligan et al.23
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